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“I used to be an adventurer like you 
but then I took an arrow in the knee” 
-Guard
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ABSTRACT  
 
Cancer usually arises through mutational changes in the genome but also epigenetic changes can 
contribute to tumorigenesis. In this research we studied both sporadically occurring and familial 
colorectal, endometrial and gastric tumors. Sporadic tumors were divided into separate categories 
depending on the microsatellite instability status of the tumor. In addition to sporadic tumors we 
studied tumors from patients with different cancer syndromes: Lynch syndrome, Familial 
colorectal cancer type X and Familial site-specific endometrial cancer. Lynch syndrome patients 
have a predisposing germline mutation in one of the mismatch repair genes (MLH1, MSH2 or 
MSH6) and the tumors are typically microsatellite unstable. Despite the extensive research efforts, 
the genetic or epigenetic background of the other studied syndromes is not known and remains 
to be molecularly characterized. We therefore explored the possible epigenetic basis of cancer 
susceptibility in these syndromes. 
First we studied the promoter methylation of 24 established tumor suppressor genes. 
Hypermethylation patterns were found to be characteristic of each tissue and diversely 
dependent on the microsatellite instability status of the tumor, or family category. The CpG island 
methylator phenotype (CIMP) in which multiple loci are silenced by promoter methylation, was 
most evident in sporadic microsatellite unstable tumors (P < 0.001) and was present in 38% of all 
of the studied colorectal, 19% of endometrial and 29% of gastric tumors. In these tumors the CIMP 
phenotype can contribute to the genomic instability and the progression of cancer. In addition, 
despite being microsatellite stable, 50% of Familial colorectal cancer type X tumors displayed the 
CIMP phenotype. 
Our results of global hypomethylation confirm that tumors have significantly lower methylation 
levels compared to normal tissues in most of the studied patient groups (P < 0.05) and that the 
hypomethylation levels depend significantly on the microsatellite instability status of the tumors 
(P = 0.042 for colorectal and P = 0.018 for gastric tumors). The significant decrease in the 
methylation levels, observed especially in the normal tissues of Familial colorectal cancer type X 
patients, could function as a premalignant field defect, where a large area of tissue is affected by 
carcinogenic alteration, and hence promote cancer development by facilitating the accumulation 
of other lesions such as genetic mutations or other epigenetic changes in the affected areas. 
After the characterization of different DNA methylation aberrations in distinct tumor categories, 
we studied the possible mechanisms behind the observed methylation changes. We evaluated the 
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association of the expression of DNA methyltransferases DNMT1 and DNMT3B and histone 
methyltransferase EZH2 with CIMP+ phenotype and global hypomethylation patterns. Compared 
to the normal tissues, all the studied methyltransferases were significantly overexpressed in 
colorectal tumors (P < 0.001) and DNMT3B also in endometrial tumors (P < 0.001). EZH2 
overexpression was shown to associate with CIMP+ phenotype especially in sporadic colorectal 
tumors and the finding was statistically significant (P = 0.003).  
The overall aim of this research was to elucidate epigenetic mechanisms in cancer, including 
cancers of different organs and also different familial cancers. Available information on the 
epigenetic events of cancers is increasing and although the topic is under continuous study, our 
understanding of it is still limited. New knowledge in the field can increase the understanding of 
the basic tumorigenic mechanisms and thereby facilitate more specific and earlier diagnosis and 
treatment of different types of cancer. Also the potential reversibility of epigenetic states offers 
interesting possibilities for drug development.  
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INTRODUCTION 
 
Cancer is among the leading causes of death being responsible for about 15% of all deaths 
worldwide. Colorectal cancer is the third most common cancer and a significant cause of cancer-
related deaths accounting for over 690.000 deaths annually. Gastric cancer is the fifth most 
common cancer globally and endometrial cancer the sixth most common cancer among women. 
In the Finnish population, over 3850 people are diagnosed with some of these cancers every year.  
Cancer arises from the concurrent or sequential accumulation of mutations in oncogenes and 
tumor suppressor genes. These genes are essential for normal cell functions: they code for 
proteins that help to regulate cell growth and differentiation, proto-oncogenes by activating and 
tumor suppressor genes by limiting growth. The progress of a normal cell into a cancer cell is slow 
but accelerates when multiple different mutations cluster. In tumorigenesis, the function of at 
least one of the DNA repairing mechanisms will usually be lost allowing more mutations to occur. 
In tumorigenesis epigenetic changes can occur simultaneously with gene mutations. 
Epigenetics refers to the regulation of gene expression in the absence of mutational changes in 
DNA sequence through certain chemical changes such as DNA methylation and various histone 
modifications or microRNA function. In mammalian DNA methylation, an additional methyl group 
is attached to the cytosine in cytosine-guanine dinucleotides (CpG) in DNA. Gene promoter 
methylation is a normal and widely used control mechanism in cells for gene expression 
regulation. DNA methylation controls the DNA transcription of a given gene usually by blocking 
the transcription. DNA methylation is essential, for example, in embryonic development and cell 
differentiation.  
Many tumor suppressor genes are known to be inactivated by the hypermethylation of critical 
promoter region CpG sites in different cancers and other diseases. Tumor suppressor genes are 
usually not methylated in normal cells. Another DNA methylation abnormality in in cancer is global 
hypomethylation at certain repetitive sequences. The underlying causes for abnormal function of 
DNA methylation pathway enzymes resulting in DNA hyper- or hypomethylation or errors in 
histone modification pathways are not well-known at present. In this research we investigated the 
roles of different DNA methylation changes in cancers of different origins and clarify the 
underlying mechanisms of the DNA methylation changes in these tumors. 
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REVIEW OF THE LITERATURE 
 
1 Epigenetics overview 
Genetic information of an organism is encoded in the DNA sequence. Epigenetics refers to the 
regulation of gene expression through certain chemical changes such as DNA methylation or 
histone modifications or the function of noncoding RNAs, without involving mutational changes 
in DNA sequence (Brazel and Vernimmen, 2015). The genetic material, the genome, is the same 
in every somatic cell of an individual. Epigenetic events are the switches that guide and regulate 
the expression of the genotype into various visible phenotypes and functions in different cells, 
tissues and individuals (Goldberg et al., 2007), also in monozygotic twins (Castillo-Fernandez et 
al., 2014). 
The term epigenetics was first introduced in 1942 to combine the words epigenesis (‘epi’ + genesis 
= “above the development”) and genetics, and was defined as “the branch of biology which studies 
the causal interactions between genes and their products, which bring the phenotype into being” 
by Conrad Waddington (Waddington, 1942; Waddington, 1968). 
Today, epigenetic control of gene expression is thought to consist of transcriptional gene 
activation or repression and post-transcriptional gene silencing (Rivera and Bennett, 2010). 
Transcriptional events include DNA methylation (e.g. in gene or transposon silencing and genomic 
imprinting), covalent histone modifications affecting gene activation or silencing and RNA-
directed DNA methylation. Post-transcriptional gene silencing involves mRNA degradation by RNA 
interference (Murray et al., 2014). 
Epigenetic events are usually reversible (Tompkins et al., 2012). The transcriptional control of the 
gene expression has to have the potential to be switched on and off when needed. During 
embryonic development and cell differentiation cells must maintain their epigenetic flexibility to 
ensure the possibility of different tissues to form (Goldberg 2007; Heyn et al., 2013). On the other 
hand, in order to retain a normal function, a fully developed and differentiated cell must maintain 
its tissue-specific epigenetic and genetic stability and cellular form (Murray et al., 2014). 
Different epigenetic mechanisms e.g. DNA methylation and histone modifications also 
functionally interact with each other (Choi and Lee, 2013). The epigenetic identity of a cell is 
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transferred from mother to daughter cells through cell division (Goldberg et al., 2007) but the 
mechanisms still remain largely unknown.  
The maintenance of epigenetic homeostasis is a sophisticated, complex and strictly controlled 
process and the malfunction in this process may predispose to cancer or other diseases (Choi and 
Lee, 2013). 
 
1.1 DNA methylation 
DNA methylation is a normal and widely used control mechanism in cells (Jones, 2012) and it is 
associated with the silencing of repetitive and centromeric sequences and transposable elements 
throughout the genome, as well as in genomic imprinting and X-chromosome inactivation (dosage 
compensation in human females) (Portela and Esteller, 2010). DNA methylation is also actively 
used in transcriptional gene silencing, chromatin compaction and it can function as a genomic 
defense mechanism against foreign (e.g. viral) DNA in cells (Brena et al., 2006). Most mammalian 
DNA methylation involves the covalent addition of a methyl group (-CH3) to the fifth carbon of 
cytosine followed by guanine (CpG dinucleotides) to form 5-methylcytosine (5mC) in DNA (Fig. 1) 
(Rivera and Bennett, 2010). Up to 80% of all the mammalian CpGs are methylated (Ziller et al., 
2013) in most cell types, except in primordial germ cells (Seisenberger et al., 2012) and in pre-
implantation embryos (Smith et al., 2014) and approximately 20% of the autosomal CpGs 
participate in dynamic genomic regulation (Ziller et al., 2013).  
The control of gene expression through DNA methylation primarily occurs in CpG islands, which 
by definition are at least 200 bp stretches of DNA with enriched C and G nucleotide content, 
usually greater than 50%, and an observed:expected ratio over 0.6 (Takai and Jones, 2002; Wang 
and Leung, 2004). CpG islands are usually located in the promoter areas upstream to the 
transcription start site and contain transcription factor binding sites and other control sequences 
such as enhancers (Ziller et al. 2013). DNA methylation regulates the expression of these genes 
most frequently by suppressing the transcription of a gene when the protein product of the given 
gene is or is not needed (Portela and Esteller, 2010). In some cases DNA methylation is coupled 
with the transcriptional activation when it occurs at gene bodies (Hellman and Chess, 2007). 
More than 50% of the human genes contain CpG islands at their promoter regions (Vavouri and 
Lehner, 2012). Promoter CpG island methylation controls the DNA transcription of a given gene 
typically by blocking the transcription. Initiation of a gene transcription requires the binding of 
specific transcription factors to DNA (Rivera and Bennett, 2010). The attachment of methyl groups 
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to cytosines induces conformational changes in DNA and chromatin structure. As the chromatin 
becomes more condensed the transcription factors can not bind to the DNA which results in the 
suppression of gene transcription (Severin et al., 2011; Paska and Hudler, 2015). Tumor suppressor 
genes are essential for normal cell functioning (Sun and Yang, 2010). The protein products of these 
genes are needed continuously in the cell to maintain homeostasis of the tissue and promoters of 
these genes are usually not methylated. Aberrant CpG island hypermethylation in these genes is 
related to cancer as well as aging and other defects (Portela and Esteller, 2010).  
DNA methylation is also observed to regulate gene expression by either inhibiting or facilitating 
DNA strand separation during gene transcription depending on the sequence and the level of 
methylation (Severin et al., 2011). In normal cells DNA methylation is an essential control 
mechanism, for example, during embryonic development and cell differentiation (Plongthongkum 
et al., 2014). Tissue-specific differential DNA methylation occurs mostly at the non-promoter CpG 
island shores which are located upstream (~2000 bp) of the promoter CpG islands and have a 
relatively low CG content (Irizarry et al., 2009). 
DNA methyltransferases (DNMTs) are the enzymes responsible for DNA methylation (Wu and 
Zhang, 2014). DNA methyltransferases transfer a methyl group from S-adenosyl-L-methionine 
(SAM) to CpG cytosines (Fig. 1) in the DNA methylation pathway (Niculescu and Zeisel, 2002; Ulrey 
et al., 2005). DNMT3A and DNMT3B are de novo methyltransferases responsible for establishing 
new methylation patterns in CpG regions that need to be transcriptionally repressed (Okano et 
al., 1998; Okano et al., 1999). DNMT1 is a maintenance methyltransferase. DNMT1 methylates 
mainly hemimethylated DNA during DNA replication (Fig. 1) to ensure the methylation pattern 
established during the differentiation of a cell is retained (Hermann et al., 2004). To an extent, all 
DNMTs can also act as de novo and maintenance methyltransferases (Svedružić, 2011). 
DNA methylation is a reversible event. Compelling evidence suggests that TET proteins 
demethylate cytosines by catalyzing the conversion of 5-methylcytosine (5mC) to 5-
hydroxymethylcytosine (5hmC) by iterative oxidation (Guo et al., 2011). TET proteins can also 
convert 5-hydroxymethylcytosine to 5-formylcytosine (5fC) and 5-carboxylcytosine (5caC) (Ito et 
al., 2011). Restoration of unmodified cytosines takes place by either replication-dependent 
dilution or DNA glycosylase-initiated base excision repair (Cortellino et al., 2011).  
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Figure 1. Cytosine methylation. A) DNA methyltransferase (DNMT) transfers a 
methyl group (-CH3) from S-adenosyl-L-methionine (SAM) to the fifth carbon of 
cytosine and SAM demethylates it into S-adenosyl-L-homocysteine (SAH). B) DNA 
maintenance methylation during replication. DNMT1 recognizes a 
hemimethylated DNA, the newly synthesized double-stranded DNA in which only 
the parental strand in methylated, and adds a methyl group (red dots) to the 
daughter strand (green) using parental strand (black) as a template. Only CpG 
dinucleotides are shown (based on http:// 
pubchem.ncbi.nlm.nih.gov/compound/5-Methylcytosine and Long et al., 2013). 
 
 
1.2 Post-translational histone modifications and chromatin remodeling  
Chromatin is wrapped around the histone core complex which is an octamer of histone proteins 
(H2A, H2B, H3 and H4) forming a nucleosome that is the basic DNA packaging unit in eukaryotes 
(Luger et al., 1997). Histone modifications actively regulate gene expression. Histones undergo 
multiple covalent post-translational modifications in their N-terminal tails that modulate the 
nucleosome structure and function leading either to activation or repression of transcription 
depending on the amino acids involved and the number and the type of the modifications (Sharma 
et al., 2010; Rossetto et al., 2012). These modifications include lysine acetylation, lysine and 
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arginine methylation, serine and threonine phosphorylation, lysine ubiquitination and 
sumoylation and ADP-ribosylation (Strahl and Allis, 2000; Zhang and Reinberg, 2001). 
Histone methylation and demethylation correlates notably with functional genomics by the means 
of suppressed or active promoters, enhancers and gene bodies (Ernst et al., 2011). Histone tails 
get methylated in different lysine or arginine residues which associate with their distinct biological 
functions. For example lysine 27 trimethylation on histone 3 (H3K27me3) functions as a repressive 
mark that leads to chromatin condensation and reduces the transcription of affected genes 
(Ferrari et al., 2014).  H3K27 is trimethylated by histone methyltransferase EZH2 which is a 
member of the Polycomb repressive complex 2 (PRC2) (Deb et al., 2015). KDM1A is an example of 
a histone demethylase (Shi et al., 2004) and it functions as a member of the RE1-silencing 
transcription factor (REST) repressor complex, with the main function of repressing neuronal gene 
expression in non-neuronal cells (Ballas et al., 2005; Arnold et al., 2013). Removal of active histone 
marks such as H3K4me3 (Voigt et al., 2013) or various histone tail acetylations by the REST 
complex induces the recruitment of additional silencing machineries to ensure the suppression 
(Arnold et al., 2013; Zhou et al., 2013). 
While histone methylation is associated with either repressive or activating functions depending 
on the modified amino acid residue and the level of acquired methylation (Ferrari et al., 2014), 
histone acetylation usually has an activating effect on chromatin. Histone acetyltransferases 
(HATs) and deacetylases (HDACs) modify histone acetylation patterns (Verdone et al., 2005; Lopez 
et al., 2015). Acetylation affects the stability of a nucleosome by transforming the chromatin into 
a more relaxed state making space for transcription factors to bind the DNA. Acetylation also 
creates docking sites for the binding regulatory proteins facilitating gene transcription (Verdone 
et al., 2005).  
Histone variant exchange adds more complexity to this epigenetic gene regulation system. Each 
conventional histone has non-allelic variants differing by a few amino acids (Talbert and Henikoff, 
2010). These are expressed at low levels and have a specific localization, expression and structural 
and functional properties (Kamakaka and Biggins, 2005; Santoro and Dulac, 2015). 
 
1.3 Noncoding RNAs and RNA interference   
Noncoding RNAs (ncRNA) are a variable class of RNA molecules that do not encode any protein. 
They control gene expression in higher eukaryotes and affect many developmental and 
physiological processes including disease (Holoch and Moazed, 2015). NcRNAs include e.g. 
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microRNAs (miRNA), small interfering RNAs (siRNA) and long noncoding RNAs (lncRNA). MiRNAs 
and siRNAs control the silencing of gene expression through mRNA degradation or through direct 
transcriptional or translational repression. LncRNAs regulate gene expression through 
interference with RNA polymerases or by targeting chromatin-modifying enzymes (Geisler and 
Coller, 2013). 
Small ncRNAs that are 21-25 nt long are designated as miRNAs. They regulate temporal and tissue-
specific gene regulation and development through RNA interference (RNAi) in several organisms 
including humans (Storz, 2002). RNAi is an epigenetic control mechanism by which RNA molecules 
inhibit gene expression (Fire et al., 1998). In this process, RNAs typically cause the destruction of 
specific mRNAs (Khanmi et al., 2015). MiRNAs are a large class of gene products that are 
transcribed as 60-70 nt hairpin RNA precursors and typically excised to functional length by Drosha 
(Lee et al., 2006) and Dicer (endoribonucleases that recognize target mRNAs via base-pairing 
interactions) (Cai et al., 2004) and Argonaute family members (Calin et al., 2002). SiRNAs and 
miRNAs also silence genes at the transcriptional level. Promoter directed siRNAs induce 
transcriptional gene silencing in humans (Morris et al., 2004; Castanotto et al., 2005). This 
silencing is associated with DNA methylation of the targeted sequence.  
Long noncoding RNAs can be several tens of kb long and they are involved in gene silencing by 
different mechanisms (Geisler and Coller, 2013). Transcription of an lncRNA across promoter 
region of downstream of a gene may also interfere with transcription factor binding and repress 
the expression of the given gene (Martens et al., 2004). LncRNAs such as HOTAIR and XIST are 
known to interact with PRC2 (e.g. EZH2) (Zhao et al., 2008) and Trithorax group proteins (Sanchez-
Elsner et al., 2006) by recruiting them to the target site to repress or activate the transcription of 
the target gene (Rinn et al., 2007).  
 
1.4 Interplay between different epigenetic factors  
Different epigenetics pathways are intertwined and this crosstalk between different pathways is 
significant (Choi and Lee, 2013). The entire epigenetic machinery co-operates together to ensure 
that an appropriate chromatin state and accessibility is achieved and maintained so that normal 
levels of gene expression is possible (Sandoval and Esteller, 2012). 
Components of the epigenetic machineries themselves are regulated by other epigenetic factors 
such as miRNAs.  These epi-miRNAs target for example DNMTs, HDACs and Polycomb genes. 
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MiRNAs can be regulated by CpG island methylation and changes in histone modifications (Valeri 
et al., 2009).  
Genes from the X chromosome are only expressed from one parental copy in an individual. Males 
have only one X chromosome but in females the expression from only one of the two 
chromosomes is achieved by a mechanism called dosage compensation (Lyon, 1961). Dosage 
compensation in mammals is interplay between noncoding RNAs and chromatin leading to 
changes in chromatin structure and the repression of the other X chromosome in females (Heard, 
2004). 
DNA methylation is regulated by chromatin proteins and DNA methylation affects the interaction 
of chromatin proteins and DNA (Hoffmann et al., 2007). DNA methylation and chromatin 
repressive proteins act together in gene silencing and for example EZH2 possibly serves a 
recruitment platform for DNMTs (Viré et al., 2006). 
 
1.5 Epigenetic inheritance 
The term epigenetic inheritance is used in two meanings, the inheritance of the epigenetic pattern 
of a mother cell to the daughter cells during cell division (mitotic inheritance) or the inheritance 
of epigenetic marks from parent to offspring in different generations (transgenerational 
inheritance). 
All different cell types have their unique epigenetic patterns. The epigenetic identity of a cell must 
be transferred from mother to daughter cells through cell division to maintain cellular identity 
(Goldberg et al., 2007). DNA methylation patterns are known to be copied to the newly 
synthesized DNA strand by DNMT1 DNA methyltransferase using the methylated parent strand as 
a template (Fig. 1) (Leonhardt et al., 1992; Smith et al., 1992; Long et al., 2013). Watson-Crick 
base-pairing dictates that C pairs with G in DNA double-strand, so CpG sequences align and both 
strands are methylated. Similarly to DNA methylation patterns, histone modification marks have 
to be re-established on the newly synthesized histones during replication. Histone chaperone 
proteins coordinate the assembly of the chromatin alongside with the histone modifying enzymes 
which seem to be the epigenetic factors that remain associated with the DNA through replication 
rather than the parental histones (Budhavarpu et al., 2013). 
Conventionally it has been thought that epigenetic patterns are erased twice during the cell life 
cycle; firstly in embryonic cells in order to achieve pluripotency after fertilization and secondly in 
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primordial germ cells (Seisenberger et al., 2013). Pluripotent cells can give rise to all cell types in 
the bodies of developing embryos through epigenetic reprogramming (Lee et al., 2014). Now 
however, it has become evident that epigenetic marks can be inherited from parent to offspring 
at least at some scale. Two recent papers indicate that there is a massive loss of DNA methylation 
after fertilization in human embryos, but not all of the methylation marks are erased. In fact, 
demethylation of the paternal genome was found to be more remarkable than demethylation of 
maternal genome and conserved imprinted regions retained the methylation throughout the 
development (Guo et al., 2014; Smith et al., 2014). There is also evidence that some epigenetic 
modifications, hypermethylation of certain tumor suppressor genes, can also be inherited in 
germline from parent to offspring (Chan et al., 2006; Hitchins et al., 2007). The mechanisms of 
epigenetic inheritance are diverse and most of them are not well described at the present. 
 
2 Basic characteristics of cancer  
Cancer is among the leading causes of death being responsible for about 15% of all deaths 
worldwide. In 2012, 32.6 million people were living with cancer (WHO, World Cancer Report 
2014; WHO, Fact Sheet 2015). The most commonly diagnosed cancers include lung, prostate, 
colon, stomach and liver cancer in men, and breast, colon, lung, cervix and stomach cancers 
among women (WHO, World Cancer Report 2014). Cancer incidence rates are not globally 
uniform and cancer is more common in developed than in developing countries. Cancers are 
divided into different types e.g. depending on the tissue of origin. Most common cancers are 
carcinomas transforming from epithelial tissue and sarcomas from mesenchymal origin. More 
than 100 different types of cancer in humans have been described (Hanahan and Weinberg, 
2000). 
Cancer is a genetic disease which requires alterations in the genome (Hanahan and Weinberg, 
2000) and the causes of genetic defects leading to cancer initiation and development vary. 
Most cancer cases are due to behavioral and lifestyle-related factors, such as high body mass 
index, low vegetable and fruit intake, lack of physical activity, and tobacco or alcohol use 
(WHO, World Cancer Report 2014). Tobacco use is the single most important risk factor 
accounting for 20% of cancer deaths globally. In low- and middle income countries 20% of 
cancer deaths are due to viral infections e.g. hepatitis B or C and human papilloma viruses (de 
Martel et al., 2012). Cancer causing mutations are known to accumulate over the time 
(Hanahan and Weinberg, 2011). Thus aging increases the risk of developing cancer especially 
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in western countries where the life expectancy is high (WHO, World Cancer Report 2014; 
Finnish Cancer Registry; 2015). 
Most cancers, approximately 90-95%, develop and progress as sporadic cancers with two major 
driving events being accumulation of different mutational events or other errors leading to 
genomic instability and copy number abnormalities in individuals (Ciriello et al., 2013; Zack et al., 
2013). These cancers do not elevate the risk of developing a cancer in the relatives. However, in 
5-10% of cancers there is a genetic hereditable component which multiplies the risk of developing 
cancer in family members (American Cancer Society, 2014).  
In the Finnish population, 30% of males and 25% of females are diagnosed with a cancer by the 
age of 75 (Cancer Society of Finland, 2015; for the most prevalent cancers in Finland, see Table 1). 
The current 5-year relative survival rate for cancer patients is 69% in women and 66% in men in 
Finland (2013) and during the most recent follow-up period (2010-2012) the survival rates have 
improved by 4% (Finnish Cancer Registry, 2015). The prognosis, treatment and survival of the 
cancer patients however depend drastically on the affected tissue and the classification (e.g. grade 
and stage) of the tumor (Table 2). For example in Finland (2012) over 90% of the breast and 
prostate cancer patients were still alive after 5 years of the diagnosis, whereas the relative 5 year 
survival rate for pancreatic cancer was only approximately 5% (Cancer Society of Finland, 2015).  
 
Table 1. The most common cancers in Finland (in 2013).  
Primary 
cancer 
Male   Primary 
cancer 
Female   
 Order of 
prevalence 
Incidence* new 
cases/year 
 Order of 
prevalence 
Incidence* new 
cases/year 
Prostate 1. 87.2 5043 Breast 1. 92.6 4808 
Lung and 
trachea 
2. 29.3 1688 Colon 2. 14.4 1011 
Bladder 
and urinary 
tract 
3. 15.6 928 Skin (non-
melanoma) 
3. 8.9 893 
Colon 4. 15.7 899 Lung and 
trachea 
4. 12.6 884 
Skin (non-
melanoma) 
5. 13.3 886 Endometrium  5. 13.8 868 
- -  - - - - - - 
Gastric 12. 6.3 350 Gastric 15. 3.6 266 
*Adjusted for age to the world standard population, 1/100 000 people (Finnish Cancer Registry, 2015, 
www.cancer.fi/syoparekisteri/en), bold; tumor tissues included in this research.  
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Table 2. Simplified classification of solid epithelial tumors: basis of grading and staging.  
Grade of 
differentiation 
 Developmental stage Metastases on lymph 
nodes 
Metastases 
well differentiated  Cancer found on very early stages. Tumors 
visible only on inner mucosa 
no tumor cells in lymph 
nodes 
cannot be 
evaluated 
moderately 
differentiated 
 Tumor infiltrating muscle layer of the 
mucosa 
regional metastasis 
present 
no 
poorly 
differentiated 
 Tumor penetrating outside the organ but 
not to surrounding tissues 
regional metastasis 
present in several lymph 
nodes 
yes 
 
undifferentiated 
 Tumor penetrating surrounding tissues but 
not to rest of the body 
tumor cells found  more 
distant or numerous 
regional lymph nodes 
 
  Cancer metastasized to other organs OR 
primary tumor not completely removable 
  
The classification of a specific tumor depends on the tissue, and there are more detailed guidelines for each tissue type. 
Most systems stratify tumors into three to four grades (Compton, 1999) and the basis is similar for solid tissues regarding 
the developmental or metastatic stage (based on Dukes classification for colorectal cancer and TNM classification for 
gastric and endometrial cancers; Cancer Society of Finland, 2015). The table shows the main basis of the solid tumor 
classification. The more well differentiated the tumor is, the more it resembles normal healthy cells, grows more slowly 
than poorly differentiated tumors and is more unlikely to be invasive or send metastasis (Compton, 1999; Cancer Society 
of Finland, 2015; Diaz-Cano, 2015).  
 
 
In the light of new research, the diagnostics and treatment methods of cancer are continuously 
improving, and it is reflected on the improving prognosis and survival of the cancer patients. 
Primary treatment in many types of solid tumors is surgery. Other treatments include radiation 
therapy and chemotherapeutics including cytotoxic drugs, hormones or interferons as well as 
palliative care all of which can be used in different combinations (Cancer Society of Finland, 2015). 
New knowledge of different cancer types provides the possibility of more personalized treatment 
depending on the molecular basis of that specific tumor. 
Multiple acquired aberrations are required for cells to become malignant. Cancer cells have 
characteristic abnormal abilities allowing them to grow and transform into malignant tumors. 
These include sustaining proliferative signaling, evading growth suppressors, activating invasion 
and metastasis, immortal replicative potential, sustaining angiogenesis and resisting apoptotic 
signals (Hanahan and Weinberg, 2000; Hanahan and Weinberg, 2011). In addition to these, cancer 
cells are able to reprogram energy metabolism in the cells and can evade immune destruction 
(Hanahan and Weinberg, 2011). These capabilities evolve due to genomic instability, mutations 
and tumor-promoting inflammation. Cancer cells are tricky little bastards since they possess the 
ability to make their neighboring normal cells create a tumor microenvironment where the tumor 
cells can thrive (Hanahan and Weinberg, 2011).  
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3 Cancer genetics  
Cancer is considered a genetic disease. The transformation of a normal cell into a tumor cell is a 
multistep process, from pre-cancerous lesions to malignant tumors and it is the result of different 
aberrations in genetic and epigenetic processes (Hanahan and Weinberg, 2000; Hanahan and 
Weinberg, 2011). Cancer arises from concurrent or sequential accumulation of mutations in 
different oncogenes and tumor suppressor genes. These genes are essential for normal cell 
functions: they code for proteins that help to regulate cell growth, proliferation and differentiation 
or cell death, proto-oncogenes by activating and tumor suppressor genes by limiting growth. 
Mutations can be classified as driver mutations which are responsible for cancer growth and 
metastasis and passenger mutations which do not affect the growth (Vogelstein et al., 2013; Marx, 
2014). Tomasetti et al. (2015) have calculated that as few as three mutations in any of the 
approximately 140 known driver genes can be enough for cancer development (Vogelstein et al., 
2013). Besides mutations in oncogenes and tumor suppressor genes the changes involving 
genomic instability (chromosomal or microsatellite instability) have been characterized in multiple 
cancers (Hanahan and Weinberg, 2011). In addition to genetic changes, simultaneously occurring 
epigenetic changes (Paska and Hudler, 2015) facilitate the aberrant expression of tumor 
suppressor genes and oncogenes and contribute to the genomic instability of cancer cells. These 
are more discussed in later chapters.   
The progress of a normal cell into a cancer cell is slow but accelerates when multiple different 
mutations and epigenetic aberrations cluster (Tomasetti et al., 2015). Tumorigenesis is also faster 
if a critical cancer predisposing defect is inherited in birth and is thus in every cell of an individual. 
During tumorigenesis, the function of one or more of the DNA repairing mechanisms can be lost 
allowing more alterations to occur (Hanahan and Weinberg, 2011).  
 
3.1 Tumor suppressor genes 
Tumor suppressor genes (TSGs) control gene differentiation and growth by limiting e.g. 
proliferation, motility or invasion (Sun and Yang, 2010). TSGs function e.g. as intra- or intercellular 
signaling molecules, DNA repair proteins, checkpoint proteins or on the apoptotic cascade. TSGs 
regulate the cell cycle by arresting it for example in the case of DNA damage (Macleod, 2000). 
TSGs also direct cells to apoptotic pathways when the damage cannot be repaired and the cell 
needs to be eliminated (Sancar et al., 2004). 
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Tumor suppressor genes are often silenced in tumors, and TSG inactivation is a frequent 
component of many hereditary cancer syndromes. TSG inactivation occurs usually by deletions, 
mutations or promoter methylation (Boland and Goel, 2010). According to Knudson’s two-hit 
theory, both alleles of TSGs have to be inactivated in order to cause aberrant gene function 
(Knudson, 1971). This theory explains the relationship between hereditary and sporadic cancers. 
In their study Knudson explained how an individual will develop retinoblastoma if they either 
inherit one mutated RB1 gene allele from the parent and one allele copy is lost by random somatic 
mutation, or if they randomly acquire mutations separately in both alleles. According to this 
theory, only one intact allele is enough to maintain its function while the faulty allele does not 
induce cancer formation. The recessive nature is the functional basis of many of the TSGs (Fig. 2). 
However, mutations in tumor suppressor genes can also be dominant-negative preventing the 
function of the wild-type allele (Goh et al., 2011), or they can involve a gain-of-function or be 
haploinsufficient when the product of only one working allele is insufficient to fulfil the 
functionality needed in a cell (Ramdzan and Nepveu, 2014); in these cases only one hit may be 
sufficient for TSG inactivation.  
Tumor suppressor genes are divided into gatekeepers, caretakers and landscapers (Kinzler and 
Vogelstein, 1997; Kinzler and Vogelstein, 1998). Gatekeepers directly inhibit cell proliferation and 
tumor growth and promote cell death (e.g. APC gene associated with familial adenomatous 
polyposis).  In each cell type there is only a few gatekeepers and individuals with a pathogenic 
hereditary mutation in these genes have a significantly higher risk (>103) of developing tumors 
than the rest of the population. The inactivation of caretaker genes leads to the disruption of the 
genomic integrity causing genetic instability through increased mutation rates in other genes 
which further promote neoplasia formation (e.g. MMR genes predisposing to Lynch syndrome; 
see chapter 3.3.2.1).  In these cases the familial risk is usually 5‒50-fold greater than in general 
population (Kinzler and Vogelstein, 1997). Landscaper defects change the microenvironment 
which facilitates tumorigenesis (e.g. SMAD4 and PTEN in juvenile polyposis syndrome or ulcerative 
colitis, where normal epithelial cells are at increased risk of neoplasia formation) (Kinzler and 
Vogelstein, 1998). 
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Figure 2. The two-hit theory of cancer causation. A) Normal cells have two undamaged chromosomes 
one inherited from each parent. The loss of function of tumor suppressor genes requires two ‘hits’ i.e. 
both alleles need to be inactivated. Individuals with hereditary susceptibility to cancer have inherited 
one mutated allele from either of the parents, so the first ‘hit’ is already present in each cell of that 
individual. In sporadic cases the first ‘hit’ is acquired by chance. In both cases, if cell acquires mutation 
to the remaining wild-type chromosome, the second ‘hit’, the cell can become tumorigenic: B) Here 
maternal (M) chromosome (pink) harbor one mutated allele of a gene (blue star). Paternal allele (green) 
is intact and the site is heterozygous. Silencing of paternal (P) allele can be obtained by multiple ways; 
1-3) loss of heterozygosity by whole chromosome loss in mitosis, through mitotic recombination or gene 
conversion through which the mutated allele replaces the wild-type allele or by deletion. Loss of gene 
function can also be acquired by 4) somatic mutation (yellow star) or 5) by epigenetic silencing (red star) 
(Based on Knudson, 1971; Aittomäki and Peltomäki, 2006). 
 
 
3.2 Oncogenes  
Proto-oncogenes are genes that promote cell growth, proliferation and inhibit differentiation and 
cell death by encoding for example growth factors or growth factor receptors, cell cycle regulators 
or signaling molecules and are essential for regulating cell proliferation or survival and the 
maintenance of tissues in normal cells (Boland and Goel, 2010). Proto-oncogenes become cancer 
promoting oncogenes when they are inappropriately activated (Adamson, 1987; Weinstein and 
Joe, 2006). Proto-oncogenes can become oncogenes by point mutations resulting in hyperactive 
protein or promoter function leading to increased transcription (Croce, 2008). Oncogenes can also 
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be overexpressed due to gene or promoter region amplifications or through genomic 
rearrangements such as translocations. These changes result in copy-number changes and excess 
of the protein, fusion proteins with oncogenic activity, or through epigenetic mechanisms 
affecting promoter function. Proto-oncogenes are dominant in nature but are only rarely 
responsible for hereditary cancers (Hodgson, 2008). 
 
3.3 Genomic instability  
Genomic instability is an integral component of human neoplasia (Lengauer et al., 1997). All 
somatic cells in an individual contain a fixed number of chromosomes which harbor the genes. A 
cell has machineries to maintain its genomic integrity, the euploidy of the chromosomes and the 
nucleotide sequences in the DNA throughout cell divisions. Different factors can contribute to the 
loss of genomic integrity. Alterations in the genome may be due to external environmental or 
chemical stress, radiation, diet, reactive oxygen species (Sancar et al., 2004), defects in DNA repair 
machineries or errors during mitosis (chromosome segregation).  
High fidelity DNA synthesis and repair is necessary to maintain genetic information from 
generation to generation and to avoid mutations that cause cancer and other diseases (Kunkel, 
2004). The cell itself can also make mistakes in reading and copying DNA. The average baseline 
mutation rate in the normal somatic cell cycle is 10-9 mutations per nucleotide base pairs, per 
cellular generation (Albertini et al., 1990). The intrinsic spontaneous mutation rate is insufficient 
to account for the all the mutations required for tumorigenesis so cancer cells have to acquire 
genomic instability in order to increase the rate of new mutations (Loeb et al., 2003).  
DNA repair mechanisms correct different aberrations in the genome of normal cells. DNA damage 
activates DNA repair complexes which recognize and eliminate the damage while DNA damage 
checkpoints arrest the cell cycle progression until the damage is repaired (Sancar et al., 2004). If 
the repair machineries do not detect the errors in the DNA the errors are copied during the DNA 
replication and passed to daughter cells during cell division. 
Different kinds of DNA repair mechanisms repair different kinds of lesions or damage in DNA. 
Double-strand breaks are usually repaired by double-strand break repair such as homologous 
recombination or non-homologous end-joining mechanisms. Direct repair of replication errors is 
conducted by mismatch repair. Nucleotide excision repair and base excision repair including single 
strand break repair act by removing damaged bases and O6-methylguanine-DNA 
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methyltransferase (MGMT) removes O6-alkylation adducts and restores the guanine to its normal 
state (Sancar et al., 2004; Iyama and Wilson, 2013).  
There are at least two different types of genomic instability: chromosomal instability (CIN) and 
microsatellite instability (MSI). Chromosomal instability is a dominant trait while microsatellite 
instability is recessive (both discussed more in chapters 3.3.1 and 3.3.2; Casares et al., 1995; 
Lengauer et al., 1997). It has been proposed (Stephens et al., 2011) that there is an additional 
mechanism affecting genome stability. The phenomenon called chromothripsis was first observed 
in chronic lymphocytic leukemia. It distorts the euploidic state of the cell by a massive catastrophic 
event in which a whole chromosome or a chromosome arm is shattered into pieces almost 
simultaneously and is reassembled randomly together by DNA repair mechanisms, creating 
deletions of some segments and complex rearrangements of the others. Chromothripsis has been 
seen to be present in 2-3% (Zhang et al., 2015a) of all cancers and it causes oncogene 
amplifications, tumor suppressor gene deletions and the heterogeneous loss of heterozygosity 
(Maher and Wilson, 2012). Chromothripsis has been found to be involved in colorectal as well as 
in other cancers (Forment et al., 2012; Kim et al., 2015). This model opposes the conventional 
theory of cancer progression through the accumulation of somatic mutations over a long period 
of time. There are differing opinions about the mechanism of chromothripsis, for example Sorzano 
et al. (2013) proposed that chromothripsis could result from repetitive breakage-fusion-bridges 
rather than from a single massive chromosome breaking event. 
 
3.3.1 Chromosomal instability and loss of heterozygosity 
Chromosomal instability (CIN) is a state of genomic instability where chromosomes are unstable. 
Either one or more chromosomes can be entirely or partially deleted or duplicated causing 
aneuploidy i.e. widespread imbalances in chromosome number in the cell (Lengauer et al., 1997; 
Pino and Chung, 2010). Aneuploidy can be caused by the unequal distribution of the chromosomes 
in the nucleus due to defects in chromosome segregation during mitosis. The CIN phenotype in 
tumors correlates with poor prognosis, metastatic potential and drug resistance (Thompson and 
Compton, 2011). 
CIN is observed in most solid tumors. Aneuploidy can present as the loss or gain of a whole 
chromosome due to errors during mitosis in excess of 10-2 per chromosome per generation in 
tumors without microsatellite instability (Lengauer et al., 1997; Geigl et al., 2008). Partial 
aneuploidy arises from double-strand breaks in DNA which causes deletions or amplifications in 
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parts of the chromosome, or chromosomal rearrangements causing only a part of a chromosome 
to be inverted or translocated to another place in the same or different chromosome (Geigl et al., 
2008). Aneuploidy is a common feature in tumor cells, but all tumors with aneuploidy do not 
display CIN. The distinguishing feature between CIN positive (CIN+) and negative (CIN-) tumors is 
that the CIN phenotype in tumors causes a wide variety of different chromosomal alterations, 
whereas aneuploidy without CIN causes more clonal aberrations (Bakhoum and Compton, 2012). 
CIN can arise from defects in mitotic checkpoint (spindle assembly checkpoint) signaling (Pino and 
Chung, 2010). This results in no delays in the cell cycle before the onset of anaphase and hence 
the duplicated chromatids may not be properly aligned on the metaphase plate before their 
division. CIN-suppressor genes (e.g. PIGN, MEX3C and ZNF516 all located on chromosome 18q) 
may be deleted leading to the silencing of these genes which causes DNA replication stress, 
structural chromosome abnormalities and defects on chromatin segregation (Burrell et al., 2013). 
Missegregation can also arise through specific kinetochore-microtubule attachment errors 
(Thompson and Compton, 2011). 
CIN can also be driven by telomere dysfunction or inactivating mutations in DNA damage response 
genes responsible for cell cycle arrest such as ATM, ATR, BRCA1/2, TP53 or MRE11 (O’Hagan et 
al., 2002; Pino and Chung, 2010). Without telomere end protection, chromosome ends enter 
breakage-fusion-bridge cycles which can lead to genome reorganization over multiple cell 
generations. In CIN tumors, a specific set of tumor suppressor genes and oncogenes critical for 
tumorigenesis are mutated. Whether these mutations drive CIN or alternatively, CIN drives the 
accumulation of these mutations is not clear. 
CIN is characterized by and can be detected as loss of heterozygosity (LOH) (Pino and Chung, 
2010). LOH means that a heterozygous locus, a whole chromosome or parts of it, is lost and the 
genetic material is present in only one copy. LOH can result from deletions, mitotic recombination 
errors or gene conversion events (Fig. 2). LOH can cause TSG inactivation but a silencing somatic 
alteration of the remaining allele is still required for tumorigenesis. LOH can be studied by 
comparing normal and affected tissue of the same individual for example by fragment analysis 
(Aittomäki and Peltomäki, 2006). 
 
3.3.2 Microsatellite instability  
Microsatellites are simple short repetitive nucleotide sequences, usually mono- or dinucleotide 
repeats that are abundant throughout the genome (Ellegren, 2004). Microsatellite sequences are 
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polymorphic in the population, but unique and uniform in each individual and hence they have 
been deployed in allele discrimination analyses, gene mapping as well as in forensics (Sharma et 
al., 2007). Microsatellite instability (MSI) is a hypermutable phenotype that is due to MMR 
deficiency (Boland and Goel, 2010). MSI is observable at the nucleotide level as deletions or 
insertions of a few nucleotides at repetitive sequences (Peltomäki, 2001). 
MSI was described in 1993 when separate groups of scientists studied colorectal tumors (Ionov et 
al., 1993; Thibodeau et al., 1993) and was first thought to be characteristic of certain types of 
hereditary cancer syndromes. MSI was indeed the first marker to help identifying hereditary colon 
cancers (Boland and Goel, 2010). 
A subset of tumors displays microsatellite instability. Today it is known that about 15% of all 
colorectal cancers display the MSI phenotype (Xiao and Freeman, 2015), of which approximately 
3% are associated with Lynch syndrome, whereas the other 12% are of sporadic origin, most likely 
due to MLH1 promoter hypermethylation repressing MLH1 expression in the target tissues 
(Boland and Goel, 2010). Compared to cancers without MSI, colorectal cancers with MSI are more 
likely to arise in the proximal colon, present in younger patients, are poorly differentiated (Ionov 
et al., 1993; Thibodeau et al., 1993) and have better prognosis particularly in stage II and III tumors 
(Benatti et al., 2005). Hereditary and sporadic colorectal MSI cancers evolve through a similar 
pathway for developing cancer without the loss of heterozygosity (Aaltonen et al., 1993; 
Thibodeau et al., 1993). 
Microsatellite instability is conventionally studied with the Bethesda panel of 5 mono- or 
dinucleotide markers, BAT25, BAT26, D2S123, D5S346 and D17S250 (Boland et al., 1998; Umar et 
al., 2004a). The MSI-high phenotype is defined by two or more unstable markers.  
 
3.3.2.1 Mismatch repair (MMR) pathway  
The DNA MMR pathway in humans contains a specific repair machinery for the repair of base-
base mismatches or insertion-deletion loops (IDLs) caused by DNA replication errors acquired 
during the  S-phase of the cell cycle (Iyama and Wilson, 2013). Mispairing of bases can also arise 
during recombination or DNA damage. The MMR machinery consists of a family of enzymes 
(MLH1, MLH3, MSH2, MSH3, MSH6 and PMS2) with the capability to recognize and repair these 
mismatches (Jiricny and Nyström-Lahti, 2000; Modrich, 2006). 
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During DNA replication DNA polymerase can make errors especially at the sites with long 
repetitive DNA sequences, such as microsatellites, which results in one or more misincorporated 
or missing nucleotides in the newly synthesized strand (Fig. 3; Jiricny, 2006). In normal cells the 
rate of single base substitution errors during DNA synthesis is in the range of 10-6 to 10-8 for 
replicative polymerases with intrinsic proofreading and exonuclease activities (Peltomäki, 2001; 
Kunkel, 2004).  
Generally DNA polymerases proofread and correct errors during the DNA synthesis, but 
sometimes the newly synthesized DNA strand escapes the intrinsic polymerase proofreading. This 
is when the DNA MMR machinery is needed: MutSα complex (a protein duplex composed of MSH2 
and MSH6) of the MMR machinery detects base-base mismatches and short polymerase slippage 
induced IDLs whereas MutSβ (MSH2-MSH3) recognizes larger IDLs based on the structural change 
in DNA caused by the mismatch (Fig. 3) (Jiricny and Nyström-Lahti, 2000; Boland and Goel 2010). 
Binding of the MutS complex to the DNA recruits MutLα (MLH1/PMS2) or MutLγ (MLH1/MLH3) 
heterodimer which interacts with the replication sliding clamp proliferating cell nuclear antigen 
(PCNA) and the DNA polymerase complex. PCNA directs the endonuclease activity of MutLα and 
DNA polymerase which removes the wrong nucleotide and attaches the correct one (Iyama and 
Wilson, 2013). If the mismatch stays unrepaired, the single base mismatches become point 
mutations and the IDLs results in frame-shift mutations leading to a premature stop codon and a 
truncated protein in the next cell generations. 
 
3.4 Colorectal cancer  
Colorectal cancer (CRC) is the fourth common cause of cancer related deaths in Finland among 
males and females with over 2000 patients diagnosed with CRC in Finland every year (Finnish 
Cancer Registry, 2015). Worldwide CRC is the third most common cancer and a leading cause of 
cancer-related death causing over 690.000 deaths yearly (WHO, World Cancer Report 2014).  
The risk of developing colorectal carcinoma increases with age. Other risk factors include a 
western style low-fiber high-fat diet, smoking, high alcohol consumption, diabetes or a familial 
background of colorectal cancer (Weitz et al., 2005) The typical age of onset of sporadic CRCs is 
around 75 years, but with familial predisposition CRC appear at much earlier age (e.g. around 45 
years in Lynch syndrome) (Lynch and de la Chapelle, 1999). Prognosis depends on the Dukes 
classification status of the tumor. The 5-year survival rate associated with Dukes A and B tumors 
is approximately 70%, Dukes C 52% and Dukes D 12% in Finnish population (Allemani et al., 2013). 
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Figure 3. DNA mismatch repair. The figure shows the MMR repair machinery which recognizes one base 
mismatches as well as insertion or deletion loops acquired during DNA replication. Lower strand in A) is 
the parental strand and the upper is the newly synthesized daughter strand. MutSα (MSH2/MSH6) 
recognizes single base substitutions or insertion-deletion loops (IDLs) in DNA. MutSα interacts with 
MutLα (MLH1/PMS2) and recruits the DNA polymerase complex and replication factors (not shown) to 
the mutation site. The DNA polymerase complex repairs the mismatch in the daughter strand and 
continues replication. IDLs can also be detected and corrected by MutSβ (MSH2/MSH3) complex with 
MutLα or MutLγ (MLH1/MLH3) complexes. Defective mismatch repair results in the accumulation of 
mutations B) in following cell generations and contributes to genomic instability (based on Jiricny and 
Nyström-Lahti, 2000; Jiricny, 2006).
 
 
The majority of CRCs are sporadic but the CRC predisposition can also be inherited.  About 25% of 
CRC cases occur in individuals with a family history of cancer. Approximately 5% of all colorectal 
cancers are hereditary with identified inherited mutations (Gala and Chung, 2011). These patients 
harbour highly penetrant mutations in the germline predisposing them to tumor development. 
Lynch syndrome diagnosed by germline mutations in MMR genes is the most prevalent CRC 
syndrome accounting for 2-4% of all colon cancer cases (Gala and Chung 2011). Other CRC 
syndromes include e.g. familial adenomatous polyposis (FAP), MUTYH-associated polyposis, 
Peutz-Jeghers polyposis, juvenile polyposis syndrome and Cowden disease (de la Chapelle, 2004; 
Jasperson et al., 2010). 
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CRCs develop through different pathways and can be classified as CIN+/aneuploid (CIN pathway) 
or CIN-/MSI (MSI pathway) (Fig. 4) (Lengauer et al., 1998).  Most of the CRC pathogenesis develops 
through the CIN pathway (Pino and Chung, 2010). First and most common model for the multistep 
tumorigenesis in CRC (Morson, 1974; Fearon and Vogelstein, 1990) follows the CIN pathway and 
is characterized by the inactivation of the APC gene which is associated with adenoma formation 
through the activated Wnt-signaling. Subsequent mutations activating KRAS are associated with 
adenoma growth through the activated RAS downstream signaling, and deletions (or other 
alterations) of genes in chromosome 18q affect adenoma growth and progression. The biallelic 
loss or inactivation of TP53 results in the activation of the adenoma-carcinoma transition. These 
changes are accompanied with widespread chromosomal imbalances and LOH in CIN tumors 
(Fearon and Vogelstein, 1990; Powell et al., 1992; Kinzler and Vogelstein, 1996; Vogelstein et al., 
2000; Takayama et al., 2001). Subsequent mutations in TGFβR and PIK3CA drive the cancer 
formation (Markowitz et al., 1995; Samuels and Velculescu, 2004). FAP is an example of a 
hereditary syndrome typically exhibiting these types of genetic changes.  
15-20% of sporadic CRCs and most Lynch syndrome tumors arise through the MSI pathway (Fig. 
4) in which MMR deficiency causes the microsatellite instability at nucleotide level. These tumors 
frequently have mutations in TGFβR2 and BAX genes and in BRAF in sporadic cases and a have 
near diploid DNA content (Lengauer et al., 1997; Jass, 2004). The MSI pathway in sporadic CRCs 
arises likely due to MLH1 hypermethylation (Lynch et al., 2007). 
An important difference between CIN and MSI CRC tumors concerns their sensitivity to different 
chemotherapeutics. 5-fluorouracil (5-FU) has been commonly used for treating colorectal cancer 
in combination with oxaliplatin and/or leucovorin, irinotecan and capecitabine (Moertel et al., 
1995; Saltz et al., 2000; Andre et al., 2004; Twelves et al., 2005). Patients with MSI colorectal 
cancer may not benefit from 5-FU-based chemotherapy (des Guetz et al., 2007). 
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Figure 4. Genetic models for chromosomal instability (CIN) and microsatellite instability (MSI) 
pathways in colorectal cancer (modified from Vilar and Gruber, 2010). 
 
 
CRC is used as a model of tumorigenesis for other epithelial cancers while hereditary cancers are 
models for their sporadic counterparts since the mechanisms and pathways are similar. It has 
become evident that CRCs are genetically and epigenetically heterogeneous with distinct 
subgroups. Moreover, individual tumors from a given subgroup may significantly differ from each 
other, and even a single tumor may consist of multiple clones (Marisa et al., 2013). Knowledge 
about the molecular background of each tumor is essential for the right kind of treatment. 
 
3.4.1 Hereditary non-polyposis colorectal cancer syndrome (HNPCC)  
Hereditary non-polyposis colorectal cancer (HNPCC) is one of the most common cancer 
syndromes (Lynch et al., 2015). HNPCC diagnosis is based on the clinical criteria for HNPCC which 
are the Amsterdam Criteria I (AC-1), Amsterdam criteria II and the revised Bethesda guidelines 
(Table 3) (Vasen et al., 1991, Rodriguez-Bigas et al., 1997, Vasen et al., 1999, Umar et al., 2004b). 
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Patients fulfilling the clinical criteria for HNPCC are subjected to studies for MMR gene defects and 
microsatellite instability in order to verify whether they fulfill the criteria for Lynch syndrome (LS) 
and genetic counseling is recommended to the relatives.  
Previously the term HNPCC was used in place of Lynch syndrome (Lynch et al., 2015). The finding 
of MMR genes and their contribution to cancer development in HNPCC revealed two distinct 
categories of HNPCC; Lynch syndrome (LS) and colorectal cancer type X (FCCX) (both discussed 
below in more detail). In Lynch syndrome patients one or more MMR genes are mutated and they 
exhibit loss of corresponding functional MMR protein. FCCX patients meet the clinical criteria for 
HNPCC, but without evidenced loss of MMR gene function (Lindor, 2009; Shiovitz et al., 2014). 
 
Table 3. Amsterdam criteria I & II and the revised Bethesda guidelines for HNPCC 
Amsterdam criteria I 1 
At least 3 relatives with histologically confirmed CRC, at least one first-degree relative of the other two 
At least 2 successive generations involved 
At least 1 of the cancers diagnosed before age of 50 
 
Amsterdam criteria II 2  
3 or more relatives with an associated cancer (CRC, endometrial, small intestine, ureter or renal pelvis) 
2 or more successive generations affected 
1 or more relatives diagnosed before the age of 50 
1 should be a first-degree relative of the other two 
Familial adenomatous polyposis (FAP) should be excluded in cases of CRC 
tumors should be verified by pathologic examination 
 
The revised Bethesda guidelines3  
CRC diagnosed in a patient before the age of 50 
Presence of synchronous or metachronous CRC or other Lynch syndrome-related tumors, regardless of age 
CRC with MSI-high histology in a patient less than 60 years old 
CRC diagnosed in one or more first-degree relative with Lynch syndrome-associated tumor, one of these diagnosed 
before the age of 50 
CRC diagnosed in two or more first- or second-degree relatives with Lynch syndrome-associated tumor, regardless 
of age 
*for the identification of individuals who should be subjected for genetic testing for MSI and Lynch syndrome (1Vasen 
et al., 1991, 2Vasen et al., 1999 (each of the criteria must be fulfilled), 3Rodriguez-Bigas et al., 1997, 3Umar et al., 
2004b). 
 
 
3.4.2 Lynch syndrome (LS) 
Lynch syndrome (LS, previously known as HNPCC) is the most common hereditary colon cancer 
syndrome accounting for 2-4% of all colon cancer cases (Peltomäki, 2001; Gala and Chung, 2011). 
LS is characterized by deficient DNA mismatch repair, early onset of cancer (approximately 20 
years earlier than sporadic cancers) and with increased risk of multiple cancers of different organs 
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including endometrial, ovarian, gastric, small bowel, upper urologic tract and pancreatic cancer 
(Familial Cancer Database, 2015). LS tumors are most likely located in the proximal colon, 
colorectal neoplasms are non-polypoid and numerous synchronous and metachronous tumors are 
present. LS is identified by molecular screening of patients fulfilling the Amsterdam criteria or the 
revised Bethesda panel for HNPCC (Watson and Lynch, 1994; Lin et al., 1998; Watson and Riley, 
2005; Gylling et al., 2007; Gala and Chung, 2011; Lynch et al., 2015). 
Inherited autosomal dominant germline mutations in the MMR genes predispose to Lynch 
syndrome (Jacob and Praz, 2002; Worthley et al., 2005; Barnetson et al., 2006). MMR protein 
deficiency causes the lack of functional DNA mismatch repair and microsatellite instability (see 
chapter 3.3.2). Affected genes in Lynch syndrome are MLH1 (42%), MSH2 (33%), MSH6 (18%) and 
PMS2 (7.5%) (Plazzer et al., 2013) in which one altered allele is inherited from either of the 
parents. Also, the germline deletion of 3’ exons of EPCAM can result in Lynch syndrome by causing 
somatic methylation and inactivation of MSH2 (Ligtenberg et al., 2009). In the Finnish population 
32 different mutations in MLH1, 9 in MSH2, 5 in MLH6 and 2 in PMS2 have been described 
(InSiGHT database, 2015). The Finnish mutations include three MLH1 founder mutations 
originating from a single Finnish individual: 3.5 kb deletion of exon 16 and flanking introns (Mut1), 
a single base substitution at a splice acceptor site in exon 6 (c.454-1g>a) (Mut2) and a c.320T>G 
substitution at exon 4 causing the amino acid change I107R (Mut3) (Moisio et al., 1996; Nyström-
Lahti et al., 1996). The mutated gene is present in every cell of these individuals and loss of 
functional MMR occurs when the wild-type allele is inactivated by a somatic mutation or an 
epigenetic event. Basically this will happen eventually in some cells. MMR deficiency contributes 
to microsatellite instability which silences tumor suppressor genes during tumorigenesis. In 
addition, a small proportion of hereditary mutations occur in other MMR genes such as PMS1 and 
MLH3 (Peltomäki, 2005; Lynch et al., 2015). Predisposed individuals have an over 80% lifetime risk 
of developing CRC (Dinh et al., 2011) which is significantly higher compared to the 2% risk of the 
general population. For extra-colonic tumors, such as endometrial tumors the risk is up to 71% 
while the ovarian cancer risk is 10-15% for the Lynch syndrome mutation carriers compared to 
1.5% or <1% of the general population, respectively (Dinh et al., 2011; Ketabi et al., 2011).  
 
3.4.3 Familial colorectal cancer type X (FCCX) 
FCCX is by definition a familial colorectal cancer syndrome characterized by patients that meet the 
Amsterdam criteria I (similar to Lynch syndrome) but without identified mutations or functional 
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loss in the MMR genes. These cancers are MMR-proficient (tested either by IHC or MSI) and the 
patients may have no increased risk for extra-colonic tumors (Lindor et al., 2005; Llor et al., 2005). 
Approximately 50% of the CRC cases meeting AC-1 are classified as FCCX (Lynch and de la Chapelle, 
2003; Lindor, 2009). Compared to LS, the mean age of onset is higher (50-60 years, compared to 
40-50 years of LS). 
FCCX tumors tends to lack the typical characteristics of CRC tumors in general such as MSI, CIN, 
active nuclear β-catenin and mutations in TP53 (Abdel-Rahman et al., 2005). FCCX tumors are less 
likely to be located in the proximal colon (compared to LS, no difference compared to sporadic 
CRC). Compared to LS, FCCX tumors show histopathologically more heterogeneous architecture, 
and are more commonly poorly differentiated than LS or non-AC-1 tumors are (Mueller-Koch et 
al., 2005; Shiovitz et al., 2014). 
FCCX pedigrees show an autosomal-dominant inheritance pattern but to date with mostly 
unknown genetic basis (Shiovitz et al., 2014). When compared to the epidemiological or 
clinicopatholological data, there are no clear features distinguishing FCCX from sporadic tumors 
(Shiovitz et al., 2014). It is still questionable whether FCCX occurs by chance due to environmental 
factors or if certain mutations are the driving force for cancer development in these patients 
(Lindor et al., 2005; Lindor, 2009) Recent genome-wide linkage scan and next-generation 
sequencing analyses have discovered germline mutations in BMPR1A and RPS20 genes in some 
FCCX families (Nieminen et al., 2011; Nieminen et al., 2014).  
 
3.5 Endometrial cancer 
Endometrial carcinoma (EC) is the sixth most common cancer in women globally (WHO, World 
Cancer Report 2014) and the fifth most common in the Finnish population. Approximately 850 
patients in Finland are diagnosed with EC every year (Finnish Cancer Registry, 2015). EC is most 
typically an adenocarcinoma which initiates with the malignant transformation of cells on the 
inner lining of the uterus. More rarely EC begins from the muscle layer of the uterus and grows as 
an endometrial sarcoma.  
The risk of developing endometrial cancer increases with age. 90% of the new ECs are diagnosed 
in patients over 50 years of age, and 50% in patients over 65 years of age. Other risk factors include 
obesity, diabetes, hormonal imbalance, hypertension, late menopause or exogenous estrogen use 
(Lynch et al., 1994; McPherson et al., 1996; Grénman and Leminen, 2013; Tiitinen, 2013). Most of 
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the EC patients are cured because EC is often diagnosed in its early stages. The survival rate after 
5 years from diagnosis is approximately 80% (Cancer Society of Finland, 2015). 
Approximately 90% of ECs are sporadic and 10% hereditary. EC in a first-degree relative increases 
ones risk of developing EC by 3-fold (Gruber and Thompson, 1996). Family history of EC also 
increases the risk of developing colon cancer. This suggests that genes involved in familial CRC 
may play an important role in EC tumorigenesis. There is a 50% risk of developing EC in Lynch 
syndrome mutation carriers. MSH6 germline mutations are associated with high risk of EC and 
these cancers typically coexist with other Lynch syndrome associated cancers (Wijnen et al., 1999). 
Individuals with Lynch syndrome mutations are recommended to take yearly gynecological follow-
up and later hysterectomy as preventive measure. 
ECs are divided into two groups based on clinical and histopathological variables (Bokhman, 1983): 
estrogen-dependent endometrioid endometrial carcinomas (Type I; EECs) accounting for 70-80 % 
of the EC cases and non-endometrioid endometrial carcinomas (Type II; NEECs). Type I tumors are 
histopathologically endometrioid, occur typically in younger menopausal and premenopausal 
women, are lower grade and more stable than Type II serous or clear cell tumors. 
Molecular genetic evidence suggests that ECs develop through a multistep process similar to CRCs. 
ECs typically exhibit gain-of-function alterations in KRAS, BRAF, HER2/neu, β-catenin, Akt and 
FGFR2 and loss-of-function of PTEN and p53 (Okuda et al., 2010). The most frequent alterations 
in Type I tumors include the repression of PTEN and microsatellite instability. KRAS is mutated in 
approximately in 30-43%, CTNNB1 in 20-45% and ARID1A in approximately 40% of Type I tumors. 
In contrast, most typical alterations in Type II tumors include TP53 mutation or HER2/neu 
overexpression (O’Hara and Bell, 2012).  
 
3.5.1 Lynch syndrome associated endometrial cancer 
Endometrial cancer is the most common extra-colonic malignancy in Lynch syndrome accounting 
for approximately 2% of all ECs (see 3.4.2 Lynch syndrome; Koornstra et al., 2009). Individuals with 
pathogenic germline MMR gene mutation (MLH1, MSH2 or MSH6) are prone to develop ECs in 
association with CRC and other tumors. The lifetime risk of MMR mutation carriers developing EC 
is up to 71% which means a 47 times higher risk compared to 1.5% of the general population 
(Strafford, 2012). Heterozygous mutations of MSH6 are associated with 44-61% of risk of 
developing EC, while the risk of CRC is only 30% in female MSH6 mutation carriers (Ramsoekh et 
al., 2009; Baglietto et al., 2010). The age of diagnosis of LS associated EC patients is approximately 
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20 years earlier than in the individuals without MMR deficiency (Marra and Boland, 1995; 
Schweizer et al., 2001).   
 
3.5.2 Familial site-specific endometrial cancer (FSSEC) 
There are families that show clustering of endometrial carcinoma without any other associated 
cancers. These ECs are called familial site-specific endometrial carcinoma (FSSEC) (Sandles et al., 
1992). According to the study of Ollikainen et al. (2005) germline mutations in MMR genes were 
present in less than 10% of the families with familial clustering of EC only. In most cases of FSSEC 
it is not known whether there is a specific heritable molecular background behind these cancers 
or if they occur as part of another syndromes yet to be described.  
 
3.6 Gastric cancer 
Gastric cancer (GC) is a common reason for cancer-related deaths and it is the fifth most common 
cancer worldwide (Ferlay et al., 2015; WHO, World Cancer Report 2014). Approximately 1000 new 
patients are diagnosed with GC in Finland every year (Cancer Society of Finland, 2015). 95% of the 
diagnosed GCs are adenocarcinomas, the rest are lymphomas or other rare cancers (such as 
carcinoid tumors or gastrointestinal stromal (GIST) tumors) (Finnish Cancer Registry, 2015). The 
incidence of GC is lower than for example in colorectal or endometrial cancers, but the death rate 
of GC is relatively high.  
GC is defined as intestinal, diffuse or non-classified based on its microscopic evaluation. Different 
GC types differ slightly by behavior. Diffuse GC appears typically at an earlier age than intestinal 
GC. Prognosis is better with intestinal GC, but the overall 5-year survival rate is worse. Only 30% 
of patients diagnosed with intestinal GC are alive after 5-year period (Laurén, 1965; Eto et al., 
2006; Ristamäki et al., 2010). Intestinal GC is prone to metastasizing to the liver and diffuse GC to 
the lymphatic vessels. Risk for developing GC increases by age. Other risk factors include salted 
and smoked food, depletion of certain vitamins, pernicious anemia and inflammation induced by 
Helicobacter pylori infection, peptic ulcers, Ménétrier’s disease and smoking (Neugut et al., 1996; 
Jakszyn and Gonzalez, 2006; Tsugane and Sasazuki, 2007). 
Gastric cancer is morphologically a very heterogeneous disease (Carneiro, 1997). Most cases of 
GC are sporadic in origin and familial clustering accounts for approximately 10% of the cases (Palli 
et al., 1994; Ekstrom et al., 2000). Chromosomal aberrations such as deletions, amplifications and 
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loss of heterozygosity affect multiple genes in GC. Most commonly affected genes in GC 
progression are APC, TP53, and NME1 all with over 30% of frequency and ERBB2 (also known as 
HER2/neu) (Gazvoda et al., 2007; Kaur and Dasanu, 2011). A single hereditary GC syndrome, 
Hereditary diffuse gastric cancer (HDGC), accounting for <3% of inherited GC cases is identified 
(Guilford et al., 1998). 40% of HDGC families harbor germline mutation in CDH1 gene and the rest 
of the cases fulfilling the clinical criteria for HDGC remain to be molecularly characterized. GC is 
also included in the Lynch syndrome tumor spectrum (Gylling et al., 2007) and LS patients have an 
increased risk for developing intestinal type GC. Other hereditary syndromes with increased risk 
of GC include Li-Fraumeni syndrome, Peutz-Jeghers syndrome and FAP (McLean and El-Omar, 
2014). 
 
4 Cancer epigenetics 
Cancer research has traditionally focused on genetic defects but during the last decades 
epigenetic deregulation has been recognized as an important player in this field. Epigenetic 
regulation is involved in every step of tumorigenesis from tumor initiation through cancer 
development to expansion and metastasis (Sandoval and Esteller, 2012). 
The role of DNA methylation (hypermethylation, hypomethylation and loss of imprinting) in 
tumorigenesis is well evidenced and the knowledge of different methylation events in cancer has 
accumulated during the past decades. The roles of other epigenetic mechanisms as well as the 
interplay between different epigenetic systems are an area of interest and under continuous 
study. 
 
4.1 DNA hypermethylation in cancer  
The function of tumor suppressors is often lost in cancers, enabling uncontrolled cell proliferation, 
division and growth. In addition to alterations in the genome tumor suppressor genes can also be 
silenced by promoter DNA hypermethylation (Stefansson and Esteller, 2013).  
Many tumor suppressor genes are known to be methylated in the critical CpG sites in their 
promoter CpG island regions especially in sporadic cancers (Toyota et al., 1999; Suvá et al. 2013). 
Increased DNA methylation levels can be due to e.g. increased DNMT activity or carcinogen 
exposure. According to Knudson’s two-hit theory (Knudson, 1971) two hits are required for tumor 
suppressor genes to be silenced, one for both alleles. Promoter methylation can silence both 
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alleles or it can serve as either of these hits accompanying one mutated allele especially in the 
case of hereditary cancers (Peltomäki, 2012). Aberrant TSG CpG island hypermethylation is 
associated with transcriptional repression and loss of gene function (Esteller, 2008). 
Several hundred to over a thousand CpG islands are found to be differentially methylated in 
different type of tumors (Kalari and Pfeifer, 2010).  Tumors with extensive CpG island 
hypermethylation can be classified as displaying the CpG island methylator phenotype (CIMP; 
Toyota et al., 1999). The CIMP phenotype was originally defined by a set of DNA sequences known 
to display differential methylation in tumor and normal colorectal tissues (MINT1, MINT2, 
MINT12, MINT17, MINT25, MINT27 and MINT31) of which at least three had to be methylated in 
a tumor in order for it to be defined as CIMP positive (Toyota et al., 1999). CIMP+ tumors also 
have a high incidence of p16 (encoded by CDKN2A) and THBS1 methylation, and also MLH1 
methylation is seen in sporadic MSI tumors. The definition of CIMP or a gene panel to test for it is 
not uniform and several panels exist for determining the CIMP phenotype of a tumor (e.g. Issa, 
2004; Joensuu et al., 2008; Ogino et al., 2009). CIMP+ pathway is suggested to be the third 
pathway for genome-wide instability after CIN and MSI in cancers (Guan et al., 2013).  
Epimutations, the heritable changes in gene expression through epigenetic aberrations, in MLH1 
(Hitchins et al., 2007; Gylling et al., 2009) or MSH2 (Chan et al., 2006) leading to silencing of the 
affected allele have been described in some individuals with MSI tumors.  
Also e.g. the deletion of 3’ exons of EPCAM is evidenced to cause epimutation and inactivation of 
MSH2 (Ligtenberg et al., 2009). Some of these epimutations seems to affect the germline, albeit 
frequently mosaic (Hitchins, 2015), and can possibly be passed through generations (Chan et al., 
2006; Hitchins et al., 2007). 
 
4.2 DNA hypomethylation in cancer 
CpG hypomethylation was the first epigenetic abnormality recognized in human tumors, but the 
biological significance of tumor hypomethylation was not a particular area of interest for 
researchers who rather focused on hypermethylation events in tumor suppressor genes (Gama-
Sosa et al., 1983; Feinberg and Vogelstein, 1983).  
Global hypomethylation is a common feature in tumors. Loss of CpG methylation can activate 
oncogenes or when present globally, hypomethylation can promote tumorigenesis by inducing 
chromosomal instability (Feinberg and Vogelstein, 1983; Portela and Esteller, 2010). 
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Hypomethylation at repetitive DNA sequences or transposable elements accounts for most of the 
global hypomethylation observed in cancer. The most frequently observed hypomethylated sites 
in cancer are tandem centromeric satellite α, juxtacentromeric satellite 2, long interspersed 
nuclear elements (e.g. LINE-1) and interspersed Alu sequences (Ehrlich, 2009). Less frequently 
hypomethylation is seen in gene regions or CpG island promoters and mostly on oncogenes 
including transcription control sequences (Wasson et al., 2006, Wilson et al., 2007).  
Global hypomethylation is associated with tumor progression but it can also be found in early 
carcinogenesis (Feinberg et al., 1988; Foy et al., 2015). Metastases are more susceptible to global 
DNA hypomethylation than primary tumors (Qu et al., 1999). Hypomethylation of repetitive DNA 
is almost always accompanied by DNA hypermethylation of tumor suppressor genes, both 
promoting aberrant tumor cell proliferation and for example the loss of imprinting (Jelinic and 
Shaw, 2007). Hypo- and hypermethylation events occur in the same tumors and seem not to be 
random, but the mechanisms behind these events are poorly understood. 
 
4.3 Other epigenetic events in cancer 
The interactions between epigenetics and genetics are altered in cancers. Aberrant histone 
modification patterns are common in different cancers and tumor types can be identified based 
on the histone modification patterns (Suvá et al., 2013). Genetic alterations in histone-modifying 
complexes are associated with altered epigenetic patterns and can induce global aberrant histone 
acetylation and methylation in cancer cells leading either to aberrant activation or repression 
depending on the modified site and the number of modifications (Ozdag et al., 2006). For example 
H3K27 targets loci for de novo methylation in cancer cells. Silencing of genes has been reported 
by trimethylated H3K27 alone without DNA methylation (Viré et al., 2006, Kondo et al., 2008). 
Also HDACs and Polycomb-group proteins EZH2 and BMI1 are known to be overexpressed in 
multiple human cancers and some lysine demethylases (e.g. KDM1A) have been associated with 
tumorigenesis (Berdasco et al., 2009; Bracken and Helin, 2009; Chase and Cross, 2011). 
The expression of different miRNAs has been shown to have distinct profiles in tumor and normal 
tissues and between tumor types (He and Hannon, 2004; Lu et al., 2005) and certain epigenetically 
silenced or oncogenic miRNAs are associated with cancer progression and metastasis (Lujambio 
et al., 2008; O’Day and Lal, 2010).  
Epigenetic mechanisms in disease, such as cancer, can be effectively studied with disease-
discordant monozygotic (MZ) twins. MZ twins have the same genome, but as the epigenetic 
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patterns develop differently after fertilization (Castillo-Fernandez et al., 2014) MZ studies help the 
researchers to better understand the molecular mechanisms involved in disease and facilitate the 
search for new epigenetic markers.   
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AIMS OF THE STUDY  
 
This study was conducted to identify epigenetic changes and associated factors underlying 
tumorigenesis in familial and sporadic cancers of different origins. The specific aims were the 
following: 
 
1. To investigate gene promoter methylation changes of well-characterized tumor 
suppressor genes in colorectal, endometrial and gastric tumors and to identify differences 
between familial and sporadic cases (I, II) 
 
2. To study global DNA hypomethylation in colorectal, endometrial and gastric tumors of 
different sporadic and familial backgrounds (III) 
 
3. To elucidate the underlying causes and mechanisms behind aberrant DNA methylation in 
colorectal and endometrial tumors and endometrial hyperplasia (I-IV) 
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MATERIALS & METHODS 
 
1 Patients and samples 
This study was conducted on a number of cancer specimens with corresponding normal tissues 
and blood samples (for the number of patient material used in each study see Table 4). 
Commercially available cell lines were also used (description of the cell lines in Table 5). Patient 
samples had been partly characterized for MSI status, mutation screening for MMR genes (MLH1, 
MSH2, MSH6 and PMS2) and MMR protein expression in other studies (Holmberg et al., 1998; 
Kuismanen et al., 2000; Schweizer et al., 2001; Renkonen et al., 2003; Abdel-Rahman et al., 2005; 
Ollikainen et al., 2005). In this study, mutation and MSI analyses were conducted for gastric cancer 
patient samples (n=59 in study II) and immuhistochemical analyses of MMR proteins were carried 
out on gastric and sporadic colorectal patient samples (n=59 in study II and n=49 in study I, 
respectively). Additionally the DNA methylation status of endometrial hyperplasias had been 
evaluated in a separate investigation (Nieminen et al., 2009). In the study series we divided the 
samples into different groups depending on the familial background of the patient (LS, FCCX and 
FSSEC) and sporadic cancers in two groups depending on their microsatellite instability status 
(MSS and MSI). 94% (17/18) of FCCX and 84% (20/24) of FSSEC cases were microsatellite stable 
(MSS), whereas most Lynch syndrome patients displayed MSI: 88-94% in LS CRC and 55-66% in LS 
EC (varying slightly between studies I, II and IV) and 100% LS GC (in both studies II and III).  
 
Table 4. Number of the patient samples used in each study (I-IV). 
 I II III IV 
Colorectal cancer     
        sporadic MSS 35 - 55 43 
        sporadic MSI 14 - 52 14 
        Lynch syndrome 33 - 43 42 
        FCCX 18 - 18 18 
Endometrial cancer     
        Lynch syndrome 38 - 50 48 
        FSSEC 24 - - - 
        Lynch syndrome hyperplasia - - - 38 
Gastric cancer     
        sporadic MSS - 36 34 - 
        sporadic MSI - 10 11 - 
        Lynch syndrome - 13 13 - 
Total number of the samples in the  project 162 59 276 203 
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Table 5. Description of cell lines used in this research.  
Cell line Cancer type Basis of MMR defect Model for: 
HCA7 colon biallelic MLH1 methylation Sporadic CRC 
HCT15 colon homozygous MSH6 mutation Lynch syndrome CRC 
HCT116 colon hemizygous MLH1 nonsense mutation Lynch syndrome CRC 
HEC59 endometrium MSH2 mutation in both alleles Lynch syndrome EC 
KM12 colon biallelic MLH1 methylation Sporadic CRC 
K562 leukemia  - Leukemia 
LIM1215 colon hemizygous MLH1 mutation Lynch syndrome CRC 
LoVo colon homozygous MSH2 mutation Sporadic CRC 
RKO colon biallelic MLH1 methylation Sporadic CRC 
SW48 colon biallelic MLH1 methylation Sporadic CRC 
(Adapted from: Andersson et al., 1979; Joensuu et al., 2008) 
 
 
A more detailed description of the patient material and specifics of the methods, including the 
information of primers, probes and antibodies used in this study, can be found in the original 
publications (I-IV). For the summary of the methods used in each study see Table 6.  
 
Table 6. Summary of the methods used in this study. 
Methods Publications 
Bisulfite sequencing (BS) I, II, III, IV 
Combined bisulfite restriction analysis (COBRA) III 
DNA bisulfite modification I, II, III 
DNA extraction I, II, III, IV 
DNA fragment analysis I, II, III, IV 
DNA sequencing I, II 
Immunohistochemistry (IHC) I, II, IV 
Methylation-specific multiplex ligation-dependent probe amplification (MS-MLPA) I, II, III, IV 
Methylation-specific PCR (MSP) I, II 
Microsatellite instability (MSI) analyses I, II 
Multiplex ligation-dependent probe amplification (MLPA) II 
Single nucleotide primer extension (SNuPE) II 
Single-strand conformation polymorphism analysis (SSCP) II 
Statistical analyses I, II, III, IV 
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2 Genomic mutation, microsatellite instability and loss of heterozygosity analyses 
DNA was extracted from formalin-fixed paraffin-embedded (FFPE) tissue blocks (patient 
specimens) by a method modified from Isola et al. (1994) or cells (blood and cell lines) as described 
in Lahiri and Nurnberg (1991). The DNA was amplified using polymerase chain reaction (PCR) 
before further analyses. 
Exon-specific genomic sequencing was used to search for point mutations in MLH1, MSH2, MSH6, 
KRAS, BRAF and CTNNB1 and to specifically test for the MMR founder mutations, as described 
previously (Chadwick et al., 2001; Vahteristo et al., 2001; Nyström-Lahti et al., 1995). 
Single-strand conformation polymorphism (SSCP) was used to screen hot spot mutations in KRAS, 
CTNNB1 and BRAF (Deng et al., 2004; Abdel-Rahman et al., 2005). Amplified DNA was separated 
on a polyacrylamide gel and 1 x MDE Gel Solution (Cambrex BioScience Rockland Inc.) was used 
to improve sensitivity to conformational changes. Gels were stained using silver nitrate for DNA 
detection. If changes were observed in the SSCP gels, the DNA was sequenced to determine the 
nucleotide changes. 
Microsatellite instability (MSI) was studied by DNA fragment analyses using microsatellite markers 
BAT25, BAT26, D2S123, D5S346 and D17S250 (Umar et al., 2004a; the revised Bethesda panel). 
The markers were run on an automatic ABI 3730 DNA sequencer and analyzed with GeneMapper 
4.0 software (Applied Biosystems). Tumors without unstable markers were considered MSS, while 
tumors with two or more unstable markers were MSI. 
Single nucleotide primer extension analysis (SNuPE) based on MLH1 polymorphism in exon 8 
(I219V A/G polymorphism) was used to analyze LOH (Renkonen et al., 2003). SNuPE is based on 
the incorporation of a single selected dideoxy-nucleotide to produce differential extension when 
the primer is annealed next to the polymorphic sequence. LOH in APC was also studied by SNuPE 
using polymorphisms in exon 11 and flanking MSI markers D5S1965 and D5S346 (Renkonen et al., 
2005). Ratios of peak areas were calculated in normal and tumor samples of the same patient and 
values <0.6 or >1.67 were considered to indicate strict LOH (Ollikainen et al., 2005). 
In patients with a verified MMR germline mutation, multiplex ligation-dependent probe 
amplification (MLPA, SALSA MLPA kit P003, MRC-Holland; Schouten et al., 2002) was used to 
detect locus-restricted LOH following manufacturer’s standard protocols. SALSA MLPA P003 kit 
contains probes for all the exons of MLH1 and MSH2. In MLPA, DNA was first denatured after 
which the MLPA probes were hybridized to their target sequences. If a deletion was not present, 
the probe was able to hybridize with its target sequence. After hybridization the probes were 
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ligated and the ligated probes were amplified in a PCR reaction. PCR primers contain fluorescent 
labels and could be analyzed on an automatic sequencer and analyzed using GeneMapper 4.0 
software (Applied Biosystems). Relative peak values were calculated for the normal and tumor 
samples of the same patient. For LOH analysis the dosage ratio of the tumor sample was divided 
by the corresponding ratio of the normal sample and values <0.6 or >1.67 were considered to 
indicate LOH. MLPA was also used in the study of large genomic deletions (MLH1 ex16 and MSH2 
ex3-5). 
 
3 DNA methylation analyses 
Methylation-specific multiplex ligation-dependent probe amplification method (MS-MLPA, MRC-
Holland; Nygren et al., 2005) was used as the primary method for DNA methylation studies in this 
research. The SALSA MS-MLPA kits ME001 and ME001B (MRC-Holland) were used for the TSG 
promoter methylation studies (I, II, III, for the genes studied see Table 7 in Results) and the SALSA 
MLPA P300 Human DNA reference-2 probemix with FAM-labeled SALSA MLPA EK1 reagent kit 
with custom designed probes for LINE-1 and methyltransferase gene promoter methylation 
studies (III, IV) (Pavicic et al. 2012; Joensuu et al., 2015). The basis and outline of the MS-MLPA 
protocol and the interpretation of the results are explained in Figures 5 and 6; also see description 
of MLPA outline above (chapter 2 in Materials and methods).  
MS-MLPA results were validated in cell lines by bisulfite sequencing (BS), combined bisulfite 
restriction analysis (COBRA) or methylation-specific PCR (MSP). DNA bisulfite modification 
required for further analyses by BS, COBRA and MSP was conducted by CpGenome DNA 
Modification kit (Chemicon) following manufacturer’s instructions.  
BS was done using specifically designed methylation-unbiased primers on the bisulfite modified 
DNA. Both, the methylated and unmethylated samples were amplified in the PCR reaction. The 
PCR products were then sequenced to determine methylation status.  
COBRA was used to study LINE-1 promoter methylation by a modified COBRA PCR protocol 
(Chalitchagorn et al., 2004). The bisulfite modified DNA was amplified in a PCR reaction prior to 
digestion with TacI or TasI in corresponding enzyme buffer (MBI Fermentas). The digested PCR 
products were run in 4.5% NuSieve 3.1 agarose gels (Cambrex). NIH Image Software was used to 
scan and score the intensities of digested and undigested bands, and the methylation level was 
calculated as a percentage of the intensity of TaqI divided by the sum of TaqI and TasI positive 
products. 
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MSP analyses were conducted using a HotStarTaq DNA polymerase (Qiagen) following 
manufacturer’s standard cycling protocol and the bisulfite modified DNA. The PCR was done in 
parallel with a different set of primers for methylated and unmethylated target sequences. PCR 
products were visualized on an agarose gel under UV illumination. 
 
 
Figure 5. Outline of the MS-MLPA protocol. The probes are designed separately for each 
methylated target and one full length probe consists of two parts (right and left oligo probes) 
per target (black-blue-green; black is the universal primer, blue is the hybridization sequence 
of the target gene and green is a stuffer sequence). MS-MLPA is multiplexed and up to 40 
genes can be studied in one sample run. The DNA is denatured and the probes are hybridized 
to the DNA. The probes, each consisting of two parts, are then ligated to obtain one full 
length probe per gene under study. Digestion is conducted simultaneously using 
methylation-sensitive endonuclease (HhaI) which recognizes GCGC sites but does not cut if 
the site is methylated (see the difference between methylated and unmethylated targets). 
Ligated uncut probes are amplified with PCR using one universal primer pair X and Y, yielding 
DNA fragments of different lengths. PCR products are then subjected to fragment analysis 
and sample comparison (Fig. 6) (modified from Nygren et al., 2005). 
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Figure 6. Detection of DNA methylation by MS-MLPA. The figure shows one normal unmethylated tissue 
sample as a reference, and one tumor sample under investigation. Ligated probes show as peaks in the 
electropherogram. Control genes (here 15) do not have the restriction site for HhaI and always generate a peak 
after ligation, digestion and PCR, but the target genes (here 26) only generate peaks when methylated. Three 
genes in this tumor sample show DNA methylation compared to normal tissue (see the red arrows). The relative 
peak area of the ligated and digested sample is compared to the peak area of the ligated sample from the same 
tissue sample. The methylation dosage ratio is obtained as follows:  
Dm = (Px/Pctrl)Dig / (Px/Pctrl)Undig, where Dm is the methylation dosage ratio, Px is the peak area of a given 
probe, Pctrl is the sum of peak areas of all the probes, Dig is sample digested by methylation-sensitive HhaI 
endonuclease, and Undig is undigested (only ligated) sample. The obtained Dm ranges from 0 to 1, referring to 
0 to 100% methylation. We used the cut-off value 0.15 for indicating DNA hypermethylation based on the 
mean Dm in normal tissue samples +1SD (Joensuu et al., 2008).
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4 Protein expression analyses 
Immunohistochemical staining was used to study the presence or the absence of specific proteins 
in the patient samples using FAM-labelled antibodies for desired proteins with Dako EnVisionTM+ 
System-HRP (DAB) detection kit (with mouse or rabbit primary antibodies when appropriate) by 
manufacturer’s standard protocol. Nuclear protein expression was determined in tumors and 
compared to the results of normal tissue samples. Protein expression was quantified by 
percentage of stained nuclei in the specimen for MLH1, MSH2, MSH6, β-catenin (cut-off >10% 
positive nuclei), p53 (cut-off >10% positive nuclei) and Ki-67 or by using the Staining Index (SI) 
value, determined by the percentage of stained nuclei (0=0, <10=1, 10-50=2, >50=3) multiplied by 
staining intensity (range 0-3) (similar to e.g. Fluge et al., 2009), ranging from 0-9 for DNMT1, 
DNMT3B and EZH2. Nuclear stainings of corresponding normal tissues were used as reference. 
 
5 Statistical analyses 
Statistical analyses were conducted by using PASW Statistics 18 software (SPSS Inc.) (III-IV) or 
VassarStats statistical computation website (I-II). Shapiro-Wilk test was used to test the normality 
of the data. Depending on the distribution of the data a parametric (for normally distributed data) 
or nonparametric (for non normal data) test was chosen. Wilcoxon signed-rank test 
(nonparametric) or t-test (parametric) was used for pairwise analyses of correlated samples (intra-
group comparison). The significance of the difference between means of two independent groups 
were analyzed by Mann-Whitney U test (for nonparametric) or t-test (for parametric data). 
Categorical data with dichotomous variables was analyzed by Fisher’s exact test or by Chi-squared 
test. Comparison of multiple independent groups was done by using one-way ANOVA (for 
parametric data) or Welch test when the assumption of homogeneity of variances (analyzed by 
Levene’s test) was not met, followed by appropriate post hoc test (Games-Howell test) to 
determine the differing group.  Correlations were tested by Pearson product-moment correlation 
coefficient (r) for parametric or by Spearman’s rank correlation coefficient (rho) for nonparametric 
data. Two-tailed P values of <0.05 were considered significant.  
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RESULTS  
 
In this research our aim was to clarify the epigenetic changes present in cancers of different origin, 
colon, endometrium and gastric, and to define the underlying causes for these changes. We also 
wanted to analyze the extent of concordance between the epigenetic patterns of each tissue type 
in sporadic and familial tumors and if there were epigenetic differences between microsatellite 
stable and unstable tumors. 
In addition to sporadic and Lynch syndrome (LS) tumors we also had two interesting groups of 
familial cancers with HNPCC-like susceptibility i.e. Familial colorectal cancer type X (FCCX) and 
Familial site-specific endometrial cancer (FSSEC). FCCX patients have colorectal cancer meeting 
the clinical criteria for Lynch syndrome but without identified MMR gene mutations or 
accompanying extracolonic tumors. In FSSEC endometrial cancers occur in families without 
tumors of other tissues. In a previous study Ollikainen et al. (2005) found germline MMR gene 
mutations in only 8% of the families with familial clustering of EC only. MMR protein expression 
changes (MLH1, MSH2 or MSH6) were observed in 52% of the families, discordantly between 
family members. Fascinated by the observations that there could be an epigenetic basis for the 
cancer susceptibility (Suter et al., 2004; Chan et al., 2006) we studied whether certain epigenetic 
changes could be responsible for cancer initiation or progression in these familial tumors that 
remain molecularly unexplained, so far. 
 
1 DNA hypermethylation in cancer (I-II)   
We studied 221 carcinomas from sporadic and familial cases for promoter methylation of 24 
tumor suppressor genes (TSGs; Table 7) using methylation-specific multiplex ligation-dependent 
probe amplification (MS-MLPA) method (Fig. 5 and Fig 6) (ME001B kit, MRC-Holland). These TSGs 
are known to be inactivated in cancer and the genes were selected based on their published 
relevance in carcinogenesis (Verma and Srivastava, 2002; Laird, 2003). Our study series consisted 
of 100 colorectal (CRC), 62 endometrial (EC) and 59 gastric (GC) tumor specimens with 
corresponding normal tissue samples. 
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Table 7. Tumor suppressor genes studied for promoter methylation. 
Gene symbol Protein function 
APC Participates in Wnt signaling, free beta-catenin level regulator, involved in cell adhesion and 
active cell migration 
ATM Protein kinase, DNA damage sensor and damage response regulator, checkpoint signaling 
activator at double-strand breaks, apoptosis and genotoxic stresses, involved in signal 
transduction and cell cycle control 
BRCA1 Central role in DNA repair by facilitating cellular response to DNA repair, mediator of E2-
dependent ubiquitination, lipid synthesis inhibitor 
BRCA2 Involved in double-strand break repair and/or homologous recombination 
CASP8 Protease in the activation cascade of caspases responsible for apoptosis 
CD44 Receptor for hyaluronic acid, mediator of cell-cell and cell-matrix interactions, role in cell 
migration, tumor growth and progression 
CDH13 Calcium dependent cell adhesion protein 
CDKN1B Involved in cell cycle arrest, cellular response to DNA damage, regulator of cell cycle, effector 
of signal transduction pathways that control cell differentiation 
CDKN2A 
(encoding 
p14ARF) 
Induces cell cycle arrest in G1 and G2 phases, negative regulator of the proliferation of normal 
cells 
CDKN2B Regulator of cell cycle, passage through the G1 checkpoint, tightly linked and highly homolog 
to CDKN2A 
CHFR E3 ubiquitin-protein ligase, cell arrest in early prophase 
DAPK1 Calcium/calmodulin-dependent serine/threonine kinase, positive regulator of apoptosis 
ESR1 Nuclear estrogen receptor α, involved in gene expression regulation, cellular proliferation and 
differentiation 
FHIT Diadenosine 5,5-P1,P3-triphosphate hydrolase, involved in purine metabolism 
GSTP1 Involved in conjugation of reduced glutathione to a wide number of exogenous and 
endogenous hydrophobic electrophiles 
HIC1 Transcriptional repressor 
IGSF4 (=CADM1) Cell adhesion molecule 
MLH1 DNA mismatch repair protein 
PTEN Protein and lipid phosphatase, cell cycle progression and cell survival modulator 
RARB Receptor for retinoic acid, gene expression regulator 
RASSF1(A) Required for death receptor- dependent apoptosis Isoform A inhibits proliferation by 
negatively regulating cell cycle progression 
TIMP3 Metalloproteinase inhibitor 
TP73 Involved in apoptotic response to DNA damage 
VHL Transcriptional repressor, ubiquitin conjugating protein, cell cycle regulator 
(Adapted from Joensuu et al., 2008; based on www.genecards.org, www.ensembl.org)  
 
1.1 Shared and tissue-specific tumor suppressor gene methylation patterns  
Of the 24 tumor suppressor gene promoter areas studied, a great proportion were found to 
display differential methylation between the tumor and corresponding normal tissue samples 
(Table 8). 11 genes out of 24 studied were commonly hypermethylated in at least 15% of the 
tumor samples per tissue category. In general, paired normal samples showed negligible 
methylation in these genes in normal colorectal, endometrial or gastric mucosae or blood (Table 
8). If methylation was observable in the normal tissue samples, the methylation dosage ratio (Dm) 
was notably lower than in tumor samples. Out of these 11 commonly methylated genes, 10 genes 
showed frequent promoter hypermethylation in colorectal cancer (ESR1, CDH13, CHFR, RARB, 
APC, RASSF1(A), TIMP3, GSTP1, IGFS4 and MLH1), 6 in endometrial cancer (RASSF1(A), CDH13, 
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APC, GSTP1, CDKN2A and TIMP3) and 5 in gastric cancer (APC, ESR1, CHRF, TIMP3 and CDH13) 
(study I for CRC and EC; unpublished results for GC; Table 8). Overall, individual tumors displayed 
hypermethylation in 0–11 tumor suppressor genes, except one LS CRC tumor with 18 
hypermethylated loci. The average hypermethylation ratio was significantly higher in CRC (4.2 
methylated loci per tumor) compared to EC (2.7; P < 0.001) and GC (2.9; P = 0.005) (Table 9, 
below).  
The promoters of three tumor suppressor genes, APC, CDH13 and TIMP3, were commonly 
hypermethylated in all of the studied tissues. APC was hypermethylated in 35% of CRC and 37% 
of EC but showed highest frequency of methylation in GC being present in 78% of the GC tumors. 
CDH13 was hypermethylated in approximately in half of the CRC (57%) and EC (44%) tumors and 
in 26% of GC tumors. TIMP3 was also commonly hypermethylated in all of the studied tissues (18-
29%) (see Table 8). 
Some TSGs were hypermethylated in a tissue-specific manner. ESR1, RARB, IGSF2 and MLH1 
hypermethylation was characteristic for CRC, whereas CDKN2A characterized EC. RASSF1(A) was 
hypermethylated in both CRC and EC, but three times more often in EC (74%) than in CRC (24%). 
APC which was hypermethylated to some extent in all of the studied tissues, showed tissue-
specificity to GC, with a much higher percentage than seen in other tissues. ESR1 and CHFR 
hypermethylation was present in 82% and 44% of CRC and 40% and 38% of GC tumors 
(respectively; Table 8), but not in EC, suggesting specificity to the gastrointestinal tract. 
 
Table 8. Tumors with tumor suppressor gene hypermethylation shown as the percentage of each tissue 
category.  
 Colon tumors (n= 100) Endometrial tumors (n= 62) Gastric tumors (n=59) 
APC 35 % (< 0.001) 37 % (< 0.001) 78 % (= 0.004) 
CDH13 57 % (< 0.001) 44 % (< 0.001) 26 % (ns.) 
CDKN2A  21 % (ns.)  
CHFR 44 % (< 0.001)  38 % (< 0.001) 
ESR1 82 % (< 0.001)  40 % (< 0.001) 
GSTP1 22 % (ns.) 26 % (ns.)  
IGSF4 16 % (= 0.027)   
MLH1 15 % (= 0.004)   
RARB 42 % (< 0.001)   
RASSF1(A) 24 % (< 0.001) 74 % (< 0.001)  
TIMP3 27 % (< 0.001) 18 % (= 0.007) 29 % (=0.061) 
Table displaying all the tumor suppressor genes which were at least 15% hypermethylated per tissue category and 
with methylation dosage ratio (Dm) ≥0.15, corresponding to ≥15% of methylation (based on the mean Dm in normal 
tissue samples +1SD), similarly to Rashid and Issa (2004). P values for differential methylation in tumor and normal 
samples given in parentheses; ns. = non-significant. Empty designates no methylation in the given gene promoter in 
that tissue. 
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RMA (robust multiarray average) pre-processed microarray mRNA data (HG-U133 Plus 2.0 array, 
Affymetrix) from another ongoing study (Abdel-Rahman et al.) was utilized to verify that the 
hypermethylation of the studied CpG sites was in fact associated with gene silencing in cell lines. 
The TSG promoter hypermethylation results were associated with reduced or absent mRNA 
expression, as best evident for TIMP3, MLH1, RARB, CHFR, IGSF4, CDH13, and GSTP1, but the 
statistical significance was not determined (Joensuu et al., 2008; Supplementary Table 6).  
 
1.2 DNA methylation patterns in separate patient categories – dependence of methylation 
patterns on the MSI status and the familial background of cancer 
Patients were divided into smaller groups depending on their familial background of cancer or the 
MSI status of the tumor (Table 9). In these subcategories, the highest amount of methylated TSGs 
was found in sporadic MSI CRC with an average of 7.3 methylated loci per tumor. Overall the 
sporadic MSI CRC group displayed significantly higher methylation ratios compared to other CRC 
groups (P < 0.001). The average number of hypermethylated TSG promoter loci was higher in MSI 
than in MSS tumors in GC (Table 9) and the difference was statistically significant (P < 0.001). In 
ECs no clear differences were found between groups. Even though Lynch syndrome CRC also 
display MSI (in 94% of all the LS CRC tumors), the methylation ratio was significantly lower 
compared to the corresponding sporadic MSI tumors (P < 0.001) but not in GC (P = 0.614).  
 
Table 9. Average number of hypermethylated TSGs and the presence of CIMP+ phenotype in different 
patient categories. 
Patient category (n) Methylated loci* per tumor CIMP+ (in % of the 
tumors per category) 
  Average Range  
Colorectal cancer     
        sporadic MSS  35 3.5 1-8 26 
        sporadic MSI 14 7.3 3-10 79 
        Lynch syndrome 33 3.9 0-11** 27 
        FCCX 18 3.7 0-8 50 
Endometrial cancer     
        Lynch syndrome 38 2.9 0-8 18 
        FSSEC 24 2.3 0-7 17 
Gastric cancer     
        sporadic MSS 36 2.0 0-7 15 
        sporadic MSI 10 4.6 1-8 73 
        Lynch syndrome 13 4.0 2-6 31 
*out of 24 tumor suppressor gene loci studied. One locus was studied for each gene, except 2 loci for RASSF1(A). 
CIMP+, CpG island methylator phenotype (≥5/24 methylated tumor suppressor genes; see chapter 1.3 in Results). 
**plus one individual tumor with 18 methylated loci. Bold = groups with statistically significant higher 
hypermethylation levels compared to other patient categories of the same tissue.  
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1.3 CpG island methylator phenotype as a driver of tumorigenesis? 
CpG island methylator phenotype (CIMP, or tumor suppressor gene methylator phenotype) is an 
alternative mechanism causing genome-wide instability in tumors (Toyota et al., 1999). CIMP in 
our sample series was set as ≥5 methylated genes out of 24 tumor suppressors studied. 38% 
(38/100) of all CRC samples displayed the CIMP phenotype (CIMP+) and it was present also in 18% 
(11/62) of all EC and 29% (17/59) of all GC tumors. CIMP+ phenotype was much more common in 
the sporadic MSI groups (in CRC 79% and GC 73%) compared to the other patient categories (P < 
0.001) (Table 9). In sporadic MSI cases, the CIMP+ phenotype was characterized by the presence 
of MLH1 promoter methylation in both CRC and GC, which could explain the MSI through defective 
MMR repair. Of all the tumors displaying MLH1 hypermethylation (23/29), 79% also displayed 
CIMP+ (P < 0.001). Clear dichotomy in CIMP status was observed in FCCX samples and the group 
could be divided into two categories with 50% of the group displaying CIMP+ whereas the other 
half did not.  
Methylation patterns in sporadic MSI (but not MSS) cancers resembled those in LS cancers (CRC 
and GC) with the exception of MLH1 promoter methylation, which was usually not methylated in 
LS tumors. Distinct methylation patterns in sporadic MSS and MSI tumors suggest different 
developmental pathways of these cancers.  
In our study series no transgenerational or germline defect in DNA methylation was observed. 
Generally, tumors from single representatives (usually the index persons) per family were 
investigated. In the occasional cases where tumors from several family members were available, 
family-specific methylation patterns were not identified. The constitutional tissues representing 
normal cells of different lineages showed negligible methylation. Furthermore, we took a look at 
nine LS patients with both CRC and EC tumor but the tumors from the same individuals did not 
show any concordance between promoter methylation profiles when tissue-specific differences 
were taken into account. Because of the small sample size statistical analyses could not be 
conducted. 
 
2 Global genomic hypomethylation in cancer (III) 
Global hypomethylation is often observed in cancers and it may cause genetic instability and 
oncogene activation. It has been suggested that DNA hypomethylation could be one of the first 
events in tumorigenesis (Feinberg et al., 1988; Foy et al., 2015). We studied CRC, EC and GC tumors 
(n=276) and their corresponding normal tissue samples for LINE-1 hypomethylation, which is a 
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transposable element present in over 500.000 copies in the genome (~17% of the whole genome; 
Xiao-Je et al., 2015). The FCCX group was of particular interest as no cancer predisposing molecular 
defects had previously been found in it.  
Measured by LINE-1 methylation, we found a decrease in the global methylation levels of all 
tumors. Compared to the corresponding normal tissues the decrease was statistically significant 
in most cases (Table 10). The degree of LINE-1 methylation in normal mucosa showed little 
variation between patient groups (Dm 0.90–0.93) except for the FCCX group (Dm 0.84) which 
clearly differed from the remaining groups (P < 0.05). This interesting finding may suggest that 
global hypomethylation promotes cancer development as a field defect, a field of pre-malignant 
tissue harboring one potentially carcinogenic aberration vulnerable to accumulation of other 
carcinogenic defects (Bernstein et al., 2013), in the normal tissues of these patients. Inter-group 
comparisons revealed that the decreasing trend of LINE-1 methylation in sporadic CRC tumors 
with MSI to LS to FCCX was statistically significant between first and last group (P = 0.042; Dm 0.87 
and 0.80, respectively). A similar finding was observed for GC between the sporadic MSI (Dm 0.88) 
and MSS (Dm 0.79) groups (P = 0.018). 
 
Table 10. Average LINE-1 methylation (Dm) in different patient categories. 
Patient category (n) Tumor Normal mucosa P value Blood* 
Colorectal cancer      
        Sporadic MSS 55  0.85 0.93 <0.001  
        Sporadic MSI 52 0.87 0.91 <0.001  
        Lynch syndrome 43 (27) 0.84 (0.84) 0.90 (0.91) <0.001 (0.95) 
        FCCX 18 (10) 0.80 (0.80) 0.84 (0.85) <0.05 (0.89) 
Endometrial cancer      
        Lynch syndrome 50 (19) 0.88 (0.91) 0.90 (0.93) ns. (0.95) 
Gastric cancer      
        Sporadic MSS 34 0.79 0.90 <0.001  
        Sporadic MSI 11 0.88 0.90 ns.  
        Lynch syndrome 50 0.86 0.90 <0.05  
Dm = methylation dosage ratio, the values for samples with all three tissues available are marked in parentheses. 
*Blood samples were available only for LS CRC, FCCX and LS EC, in which the differences between tumor and blood 
were all statistically significant (P < 0.001, P < 0.01 and P < 0.01, respectively). ns. = non-significant. 
 
 
Tumor suppressor gene hypermethylation and global hypomethylation have been described as 
related events (Shi et al., 2007). Even though both hyper- and hypomethylation was observed in 
the same tumors, there was no clear correlation between TSG hypermethylation (I, II) and LINE-1 
hypomethylation (III) in our sample series. Overall, the results suggest that the LINE-1 methylation 
status depends on the MSI status of the different patient categories and that hypomethylation 
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may function as a field defect (Bernstein et al., 2013) when seen already in the normal mucosa, as 
in the case of the FCCX patient samples studied. 
 
3 Changes in methyltransferase activity in cancer (IV)  
After discovering changes in epigenetic patterns of different carcinomas we wanted to elucidate 
the underlying causes for aberrant DNA methylation. DNA methyltransferases DNMT1 and 
DNMT3B and histone methyltransferase EZH2 are described to be overexpressed in colorectal and 
several other tumors (Eads et al., 1999; Vallbohmer et al., 2006; Zhu et al., 2007; Fluge et al., 
2009). For example, Nosho et al. (2009) suggest that aberrant DNMT3B expression might 
contribute to the CIMP phenotype in CRC. The protein expression of three methyltransferases 
(MTs), EZH2, DNMT1 and DNMT3B, was investigated by immunohistochemical evaluation on 117 
familial and sporadic CRC, 48 EC and 38 endometrial hyperplasia samples to determine if abnormal 
expression of some of these proteins contributes to tumor suppressor gene hypermethylation, 
CIMP phenotype or the global hypomethylation patterns observed in the samples.  
 
3.1 Aberrant DNA methylation – aberrant methyltransferase patterns?  
DNMT1, DNMT3B and EZH2 were expressed at significantly higher levels (P < 0.001) in CRC tumors 
compared to their paired normal samples (mean SI values ranging from 2.65 to 5.35 for DNMT1, 
6.52–8.00 for DNMT3B, and 1.79–6.58 for EZH2 in tumors and 1.13–2.56, 0–2.11, and 0–1.33 in 
paired normal mucosa, respectively) in all studied patient categories except DNMT1 in FCCX 
patient category (not reaching statistical significance P = 0.067) (Table 11). In EC MT expressions 
were relatively low except for DNMT3B expression which was significantly higher in tumors than 
in normal endometrium (P = 0.001). DNMT1 and EZH2 expressions were discovered to be 
significantly higher in CRC than in EC tumors (mean 4.20 vs. 0.89 for EZH2 and mean 4.34 vs. 1.19 
for DNMT1 in CRC and EC, respectively; P < 0.001 in both). 
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Table 11. Mean methyltransferase protein expression (SI) in tumors in studied patient categories. 
Patient category DNMT1 DNMT3B EZH2 
 Tumor Normal Tumor Normal Tumor Normal 
Colorectal cancer       
        Sporadic MSS 3.92 1.33 6.78 0.36 1.79 0 
        Sporadic MSI 4.75 1.71 8.00 1.23 5.13 0.50 
        Lynch syndrome 5.35 2.56 6.52 0 6.58 0.14 
        FCCX 2.65 1.13 7.36 2.11 4.00 1.33 
Endometrial cancer       
        Lynch syndrome 1.19 0.73 6.50 3.33 0.89 0.17 
The values are staining index values (SI) ranging from 0-9 for DNMT1, DNMT3B and EZH2 and are obtained by the 
product of intensity of the staining (range 0–3) multiplied by the percentage of stained nuclei (0=0, <10=1, 10-50=2, 
>50=3) similar to published studies (Foulkes et al., 2003; Collett et al., 2006; Fluge et al., 2009).  
 
 
EZH2 expression was positively correlated with TSG hypermethylation (CIMP+, being ≥5 
methylated TSG promoters) in sporadic CRC tumors (P = 0.003; rho .418), whereas the expression 
of DNMT1 did not display correlation with TSG methylation status in any of the studied patients 
groups. Neither EZH2 nor DNMT1 expression correlated with the LINE-1 hypomethylation (our 
unpublished data). DNMT3B was significantly overexpressed in all tumors when compared to the 
normal tissues (P < 0.001, with the group means ranging from SI 6.50 to 8.00) but because of the 
general lack of variation observed in DNMT3B expression correlations with DNA methylation levels 
could not be calculated for groups other than the LS CRC patient group which did not show any 
significance. Although heavily overexpressed, it still seems that DNMT3B overexpression does not 
affect DNA methylation patterns at least as much as EZH2, since DNMT3B was also overexpressed 
in tumors without TSG hypermethylation. 
DNMT1 and EZH2 expression was positively correlated especially in colorectal tumors (P = 0.001; 
rho .317) suggesting co-operative functions in the epigenetic pathways of tumorigenesis. In EC the 
trend was similar (P = 0.091; rho .258). DNMT1 and EZH2 expression was higher in MSI than in 
MSS tumors as was Ki-67 expression which was studied as a proliferation marker. The difference 
between MSI and MSS tumors was statistically significant between LS CRC and FCCX for DNMT1 
(P = 0.002), and between sporadic MSI CRC and sporadic MSS CRC for EZH2 (P = 0.026). 
In endometrial hyperplasia series from Lynch syndrome patients an increasing trend in MT 
expression was observed (from simplex hyperplasia to complex hyperplasia to complex atypical 
hyperplasia) but the statistical significance could not be determined due the small sample sizes 
(Table 12). This result is in line with the finding of Nieminen et al. (2009) where TSG promoter 
methylation increases along with histological abnormality (observed in the same endometrial 
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hyperplasia samples as in this study). This suggests that the overexpression of MTs could be 
important in neoplastic formation.  
 
Table 12. Mean methyltransferase protein expression (SI) in normal endometrium, different 
endometrial hyperplastic stages and endometrial carcinoma from Lynch syndrome patients. 
 DNMT1 DNMT3B EZH2 
Normal endometrium 0.73 3.33 0.17 
Simplex hyperplasia (SH) 1.71 4.89 0.44 
Complex hyperplasia (CH) 3.00 5.22 0.44 
Complex atypical hyperplasia 
(CAH) 
3.84 7.68 0.85 
Endometrial carcinoma (EC) 2.40 7.30 2.60 
The given numbers are staining index values (SI), for description see Table 11. 
 
3.2 Looking for underlying causes for methyltransferase protein overexpression  
Since there was evidence that MT genes themselves can be regulated by promoter methylation 
(e.g. Huidobro et al., 2012) we designed a MS-MLPA probe set to study the promoter methylation 
of DNMT1, DNMT3B and EZH2 genes in our samples. The studied sites were selected from 
promoter areas or near to specific transcription factor binding sites. One of these sites, the 
DNMT3B distal promoter, showed statistically significant differential methylation between CRC 
tumors (Dm 0–0.46) and normal tissues (Dm 0–0.24; P < 0.001). DNMT3B promoter methylation 
was negatively correlated with DNMT3B protein expression in LS CRC group (the only group with 
variation in DNMT3B expression) with borderline significance (P = 0.079; rho -.358). 
We also investigated the promoter CpG island methylation of other key epigenetic pathway genes 
(DNMT3A, ΔDNMT3B, HAT1, HDAC1, HDAC2, HDAC3 and SIRT1) by bisulfite sequencing, but no 
differential methylation was found at these sites in cell lines (our unpublished data). 
We also took advantage of methylation data previously generated on the same tumors regarding 
methylation-dependent miRNA silencing (Pavicic et al., 2011) and compared the miRNA loci (miR-
152, miR-148a and miR-124a(1-3) known to target DNMT1, DNMT3B and EZH2, respectively) 
methylation results to the MT protein expressions. We did not find positive correlations between 
miRNA expressions in relation to the expression of their protein targets. 
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DISCUSSION  
 
This study was designed to investigate the epigenetic changes in familial and sporadic colorectal, 
endometrial and gastric cancers. Our study series consisted of colorectal, endometrial and gastric 
tumors from Lynch syndrome patients, colorectal and gastric tumors from patients whose cancer 
occurred sporadically, and two groups of patients with familial clustering of either colorectal or 
endometrial tumors without specified genetic defects. At first we focused on DNA methylation 
patterns in separate patient groups and we then tried to elucidate the underlying causes behind 
the observed methylation changes. 
 
1 DNA methylation in colorectal, endometrial and gastric cancers (I-III) 
1.1 DNA methylation patterns as tumor classifiers 
We examined the promoter hypermethylation of 24 established TSG loci by the MS-MLPA method. 
Methylation profiles showed tumor-specificity for a number of TSGs and tissue-specificity for 
many of those TSGs. Altogether 11 genes were differentially methylated in tumors and normal 
tissue samples. Three genes (APC, CDH13 and TIMP3) were commonly hypermethylated in 
colorectal, endometrial and gastric cancers indicating the important role of these genes in 
tumorigenesis in general. Otherwise methylation patterns differed and tumors from different 
origins could be identified by their hypermethylation patterns.  
The CIMP phenotype has been associated with MSI in previously published studies (Esteller et al., 
1998; Veigl et al., 1998; Goel et al., 2007). In these CIMP+/MSI cancers MSI is due to epigenetic 
instability inactivating key tumor suppressor genes such as MLH1 by promoter hypermethylation 
(Kane et al., 1997; Shigeyasu et al., 2015). We observed the TSG hypermethylation profiles to be 
concordant with the previously reported findings of sporadic MSI tumors displaying significantly 
more frequent tumor suppressor gene hypermethylation (and CIMP+ phenotype) compared to 
sporadic MSS tumors in CRC and GC. Our results of the CIMP and genomic instability patterns in 
CRC, EC and GC also comply with the classifications based on the comprehensive genetic and 
epigenetic characterization of the respective sporadic cancers by the Cancer Genome Atlas 
Research Network (2012; 2013; 2014). 
Compared to sporadic tumors, tumor suppressor gene hypermethylation (and CIMP) has been 
studied much less extensively in familial cancers. Our results show that the hypermethylation of 
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tumor suppressor genes is characteristic dependent on the tumor type and family category (LS, 
FCCX or FSSEC) in familial cancers. The hypermethylation patterns in Lynch syndrome tumors 
resembled those in their sporadic MSI counterparts in CRC and GC but without MLH1 promoter 
hypermethylation that was often present in sporadic MSI tumors. Lynch syndrome tumors 
generally do not require MLH1 hypermethylation in order to induce microsatellite instability 
because of an inherited germline mutation in a MMR gene that is often combined with the somatic 
deletion of the wild-type allele (LOH) in the tumors (Hemminki et al., 1994). Only two CRC tumors 
from MLH1 germline mutation carriers showed low-level MLH1 methylation (Dm 0.18) which 
could serve as the second hit inactivating the wild-type allele (Lynch et al., 2015). The frequency 
(2/27) of somatic MLH1 promoter methylation in LS CRC complies with findings reported by other 
researchers (e.g. 3/19 in Moreira et al., 2015). Despite the fact that the CIMP+ phenotype was 
mostly observed in MSI tumors and with MLH1 promoter methylation in sporadic cases, we also 
observed CIMP+ in 50% of the microsatellite stable FCCX tumors without MLH1 methylation. This 
suggests that there has to be two distinct mechanisms for the development of these tumors with 
one following the MSS/CIMP+ pathway whereas the other one may involve some other 
mechanism (see the next paragraph).  
Global hypomethylation can occur early in tumorigenesis and is often observed in cancers. 
Decrease in the genomic 5-methylcytosine content results in genetic instability and oncogene 
activation (Foy et al., 2015). LINE-1 is a transposable element present in over 500.000 copies in 
the genome (Xiao-Je et al., 2015), and it is widely used for determining the global methylation 
status of cells. LINE-1 methylation levels have been shown to decrease progressively from healthy 
tissue to adenoma to carcinoma in several studies (e.g. Park et al., 2009; Ibrahim et al., 2011). The 
global hypomethylation levels we observed were in agreement with previously published results 
and the result was statistically significant. Goel et al. (2010) reported lower methylation levels in 
CRCs from FCCX patients compared to other CRCs. Their report focused on tumor tissues only. To 
add to this, we show that interestingly, the FCCX patient group’s normal tissue samples already 
show a significant decrease in the genomic 5-methylcytosine content. Overall, our results confirm 
that the LINE-1 methylation status depends on the tissue and the MSI status and that 
hypomethylation may function as a field defect promoting tumorigenesis already in the normal 
mucosa as seen in FCCX patients. The idea that global hypomethylation may be linked to the 
hereditable predisposition to CRC is supported by epidemiological observations that patients with 
LINE-1 hypomethylation in CRC tend to have a family history of CRC (Ogino et al., 2013). Although 
the hypermethylation of specific tumor suppressor gene loci and the CIMP phenotype often co-
existed with global hypomethylation in the same tumors, the hyper- and hypomethylation profiles 
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in our studies were not statistically correlated and it is unknown whether these two seemingly 
opposite patterns are regulated jointly or independently of each other. 
 
1.2 Methodological aspects 
Cytosine methylation can be studied by a variety of different mechanisms. Conventionally most 
of the applications to study DNA CpG methylation are based on either bisulfite treated DNA or 
methylation-sensitive restriction enzymes (Jorda and Peinado 2010) (e.g. BS, MSP and COBRA also 
used in validation purposes in this research; see Materials and methods) and are laborious and 
time-consuming. Genome-wide DNA methylome assays are expensive and also often require good 
quality bisulfite modified DNA.  
 
We chose to use the MS-MLPA method for the CpG methylation studies because of the advantages 
of this method in our study and samples. MS-MLPA is based on a methylation-specific 
endonuclease, does not require DNA bisulfite conversion and works well with even short single-
stranded DNA fragments since the probes only require 50–60 bp for hybridization and the ligation 
and digestion is performed on the MS-MLPA DNA-probe complex (Nygren et al., 2005). Using MS-
MLPA, multiple target sites (up to 40) can be examined simultaneously with a single primer pair, 
which saves both sample and time. MS-MLPA allows the detection of specific methylated CpGs at 
site of interest and is ideal when you know which sites you want to study. MS-MLPA was the most 
suitable method for our sample collection in which DNA was mostly extracted from ancient FFPE 
archives since DNA extracted form paraffin blocks is fragile and usually fragmented. Each MS-
MLPA probe detects the methylation status of one or two specific CpG sites only, so the CpG sites 
to be examined by MS-MLPA have to be chosen so that their methylation status represents that 
of the surrounding larger region. We used ME001B probe set (MRC Holland) for TSG methylation 
studies and designed new probe sets for the LINE-1 and MT promoter methylation studies and 
validated the MS-MLPA results in cell lines with parallel examination by BS and additionally MSP 
(Study I) or COBRA (Study III) of the same samples. 
 
In some cases the samples sizes in our study were quite small so statistical significance could not 
be determined. In these cases however, our results provided valuable information about the 
trends which can be used when planning new studies and findings that can be further investigated 
in the future with larger sample size. Also the investigation of DNA methylation profiles with cell 
lines may give distorted results due to methylation changes, both global hypomethylation (~10-
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30% less than in human primary cells) (Ziller et al. 2013) and increased hypermethylation of TGSs 
(Varley et al., 2013) observed in the long-term cultured cell lines. 
 
 
2 Elucidating the background of methylation changes (I-IV) 
It is not known what lies behind the DNA methylation changes in cancer. In the past it has been 
described as a random phenomenon resulting from the errors in maintaining methylation patterns 
during DNA replication and selection of tumor suppressor deficient cells in the future cell 
generations. But since DNA methylation seems to be a non-random event in cancer cells it is more 
likely that methylation errors are due to specific defects in DNA methylation or demethylation 
machinery resulting in certain types of aberrant methylation. We wanted to study the possible 
roles of different methyltransferases in relation to the observed aberrant DNA methylation. We 
studied the expression of DNA methyltransferases DNMT1 and DNMT3B and histone 
methyltransferase EZH2 in CRC and EC samples. All the studied methyltransferases were 
overexpressed in tumors, especially in MSI tumors, compared to their normal counterparts. 
Surprisingly the elevated expression of DNA methyltransferases in tumors did not show any 
particular correlation with TSG hypermethylation or the CIMP phenotype. However, the 
expression of EZH2 histone methyltransferase showed significant positive correlation with TSG 
hypermethylation in sporadic CRC suggesting that EZH2 overexpression can contribute to tumor 
development via aberrant DNA methylation in sporadic but not necessarily in familial CRC. Nosho 
et al. (2009) suggested that DNMT3B expression contributes to the CIMP phenotype in CRC. The 
recent study of Sarabi and Naghibalhossaini (2015) also shows the mRNA expression of DNMTs to 
correlate with global methylation levels but their study was done on CRC cell lines and the results 
cannot be directly applied to patient samples. In our sample series DNMT1 and DNMT3B 
expression levels were also higher in cancer than in normal tissues but the expression did not 
correlate statistically with DNA methylation changes in any of the studied patient groups.  
Our data confirm previously published results in which DNMT expression changes correlated 
poorly with DNA methylation alterations in various tumor types (Eads et al., 1999; Ehrlich, 2006; 
Vallbohmer et al., 2006,) and DNA hypermethylation is mostly associated with EZH2 expression 
(Viré et al., 2006; Hoffmann et al., 2007). Hoffmann et al. (2007) reported that in prostate cancer, 
the expression changes of EZH2 are directly associated with DNA methylation changes, both 
hypermethylation of certain TSGs and hypomethylation of LINE-1, rather than DNMT1 or DNMT3B 
investigated in their study. Our findings support their finding concerning the EZH2 expression in 
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association to hypermethylation of tumor suppressor genes in sporadic CRC. However, our data 
did not confirm any association between LINE-1 hypomethylation and methyltransferase 
expressions, which might be partly due to the relatively low samples sizes. EZH2 was also found 
to correlate positively with DNMT1 expression in tumors in concordance with the study of Viré et 
al. (2006) where they proposed that these methyltransferases are co-operating in transcription 
control systems where EZH2 serves as a recruitment platform for DNMTs.  
TSG promoter methylation is shown to increase until an appropriate neoplastic state is achieved 
(Nieminen et al. 2009; Valo et al., 2015). DNMT1 and DNMT3B protein expressions investigated in 
this study followed the same pattern in the present endometrial hyperplasia series (from normal 
endometrium to SH to CH to CAH). The DNMT expressions were systematically lower in EC than in 
CAH which indicates the importance of DNA methyltransferase overexpression in the developing 
neoplasm but not necessarily anymore in the developed or malignant tumor. Our findings 
especially emphasize the role of EZH2 in tumorigenesis through associations with elevated TSG 
hypermethylation, CIMP phenotype and DNMT1 expression. The overexpression of EZH2 and 
other MTs can be one of the first events in neoplastic formation, tumor progression and 
development into malignant cancer and could be used as prognostic markers in endometrial and 
possibly other neoplasms. Targeted inhibition of EZH2 could offer a therapeutic target in cancer 
cells for preventing the aberrant hypermethylation of other genes in the developing tumor 
without altering the global methylation of the cells.  
After observing elevated methyltransferase expression levels in tumors, we set out to elucidate 
the causes for these findings. EZH2 (Fussbroich et al., 2011; Zhang et al., 2015b) and DNMT1 (Zhan 
et al., 2015) overexpression is known to associate with cell proliferation in cancer, while the loss 
of EZH2 is associated with cancer cell growth inhibition, decrease in invasion and metastasis and 
inducing senescence and apoptosis. We examined the Ki-67 proliferation marker expression in the 
samples and found that the expression changes of methyltransferases could not be explicitly 
explained by faster proliferation in all the studied patients. Inspired by the fact that 
methyltransferases themselves can be regulated by promoter methylation (Huidobro et al., 2012), 
we designed a probe set targeted for DNMT1, DNMT3B and EZH2 CpG rich areas with specific 
transcription factor binding sites for DNA methylation studies. Only one of these probes, at 
DNMT3B distal promoter, displayed differential methylation between tumor and normal samples 
and the methylation status was indeed associated with protein expression. Based on our findings, 
DNMT1 and EZH2 are apparently not regulated by promoter methylation in human primary 
samples. Several studies have shown that certain miRNAs affect the expression of the studied 
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methyltransferases. MiR-152 targets DNMT1, miR-148a DNMT3B and miR-124a(1-3) EZH2 
according to published literature (Braconi et al., 2010, Duursma et al., 2008, Zheng et al., 2012, 
respectively).We took advantage of our existing data on methylation-dependent miRNA silencing 
(Pavicic et al., 2011) but found no association between the miRNA methylation and the 
methyltransferase gene expression. However, several miRNAs target one gene so this only 
confirms that the studied miRNAs were not powerful enough to regulate the expression of these 
methyltransferases alone. 
 
3 Overall conclusion of the findings (I-IV) 
Overall, this research provided new information about the molecular epigenetic phenomena in 
cancers, especially between familial and sporadic cancers. Tissue type, MSI status and the familial 
background of the cancer determined the frequency of TSG hypermethylation mirroring different 
developmental pathways in different cancers. According to our results, TSG hypermethylation 
seems to serve as the cause of MSI in many cases of sporadic CRC and was statistically correlated 
with EZH2 overexpression. Cancer in LS cases was evidently due to the identified mutations of the 
patients, but the accompanying TSG hypermethylation may fasten the cancer development in 
these patients by affecting essential cellular pathways and in some cases serve as the second-hit 
alongside with the inherited mutation. APC (Sawa et al., 2015), CDH13 (Zhong et al., 2015) and 
TIMP3 (Guan et al., 2013) are well known to be inactivated in various cancers and are related to 
tumor growth, angiogenesis, invasion and metastasis. In our study, these genes were commonly 
hypermethylated regardless of the tissue emphasizing the importance of the silencing of these 
genes by promoter hypermethylation in the tumorigenesis of all the studied tissue types included 
in this research. Global hypomethylation was evident in tumors vs. normal tissue samples and 
blood in a tissue-specific manner. There are conflicting results regarding the role of global 
hypomethylation observed in peripheral blood (Brennan and Flanagan, 2012), but our results 
suggest that it could be one of the first visible evidence of cancer initiation as seen in the FCCX 
patients in our study series.  
DNA methyltransferase DNMT3B was overexpressed in almost all of the tumors but direct 
correlations could not be seen between the level of expression and TSG hypermethylation status 
of the samples. On the contrary, histone methyltransferase EZH2 overexpression correlated with 
the CIMP+ phenotype suggesting its role in the aberrant tumor suppressor gene hypermethylation 
of sporadic tumors. Recent evidence show the potential effect of EZH2 inhibition in treating 
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human melanoma cell lines harbouring activating mutation in EZH2 (Tiffen et al., 2015) resulting 
in reactivation of repressed TSGs in these cells. DNMT1 expression correlated positively with EZH2 
expression suggesting co-operative functions of these methyltransferases in cells. Unexpectedly 
the aberrant hypermethylation patterns in tumors did not follow the DNA methyltransferase 
expression levels. Future research should be directed to study more closely the function of the 
mechanisms directing DNMTs to DNA for target sequence methylation or marking the sites for de 
novo methylation. The activities of DNA demethylases and passive demethylating mechanisms 
should be studied more carefully in the context of global hypomethylation and cancer. Our results 
show that aberrant methyltransferase expression, notably EZH2, and DNA methylation changes 
can be detected already in early tumorigenesis in different tumors and may therefore have 
diagnostic potential.  
Methylation and other epigenetic changes can be reversed, and certain genes have been 
reactivated in cancer using demethylating agents (De Carvalho et al., 2012; Wu and Zhang, 2014). 
At present, demethylating agents, 5-azacytidine (Falchook et al., 2013) and decitabine (Garrido-
Laguna et al., 2013), are used to treat different cancers and there are at least 20 histone 
deacetylases in clinical testing (Yan et al., 2015) such as panobinostat (Bauer et al., 2014) and 
valproic acid (Falchook et al., 2013). Especially the targeted reactivation of TSGs commonly 
inactivated by promoter hypermethylation in various cancers, such as APC, CDH13 and TIMP3 also 
observed to be hypermethylated in our study, could be useful in treating different types of 
cancers. At present, there is no established therapeutics targeting the Wnt signaling pathway 
(Sawa et al., 2015). Demethylating treatments have been effective in some cancers, but it is 
difficult to target demethylating treatments to specific gene promoters only without affecting the 
whole genome methylation levels of the cell. Targeting the levels of methyltransferase proteins 
responsible for the aberrant hypermethylation might provide some more selectivity. Our study 
confirms that EZH2 is one possible target since the EZH2 protein levels were positively correlated 
with tumor suppressor gene hypermethylation in the present study and also with DNMT1 
expression which can be responsible either for de novo methylation in the tumor cells or for loss 
of imprinting that promotes accumulation of methylation defects in cancer cells (Biniszkiewicz et 
al., 2002; Jelinic and Shaw, 2007). Some EZH2 inhibitors (e.g. EPZ-6438) are already currently being 
clinically tested (Yan et al., 2015).  
Moreover, it is important to distinguish between driver and passenger effects of different genes 
in cancer (De Carvalho et al., 2012; Marx, 2014). Currently oncogenes are the major molecular 
target for anti-cancer drug design and studies exist showing that for example the restoration of a 
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caretaker tumor suppressor gene function in a cancer cell does not affect its growth (Kinzler and 
Vogelstein 1998). That has to be kept in mind when planning new molecular therapies. Based on 
our results, for example patients with sporadic CRC could benefit from the combined treatment 
with a demethylating agent and an EZH2 inhibitor. 
This study provided information on the epigenetic events, hyper- and hypomethylation in 
different types of cancers. Hypermethylation of certain genes can be used as a marker for the 
early detection of cancer. By studying prostate biopsies Paziewska et al. (2014) similarly noted 
that DNA methylation status of specific genes is a reliable marker of cancer detection and may be 
even more reliable than gene expression investigated by the most promising mRNA-based 
prostate cancer biomarkers. Tumors of different origin can be identified by their methylation 
profiles as is most evident for tumors displaying CpG island methylator phenotype. Alongside with 
genetic profiling, epigenetic profiling can be used to identify the tissue of the primary tumor in 
the case of a metastasis of an unknown origin and treatment plan can be designed accordingly. 
Observed global hypomethylation patterns suggest that hypomethylation in normal tissue can 
promote tumorigenesis, at least in mutation negative MMR proficient tumors and the decrease 
of methylation can be observed already in the blood and normal mucosa samples. This 
information may be used as a tool in cancer diagnosis. Molecular classification of tumors is 
essential for determining rational cancer treatment. Cancer is a heterogeneous disease and 
develops through multiple different pathways. Aberrations in the functions of these pathways can 
be detected by genetic and epigenetic profiling. When genetic and epigenetic profiles of a tumor 
are recognized the information can be utilized in counseling and planning of targeted treatment 
for each individual patient based on the defects of the tumor. Our FCCX tumor global 
hypomethylation results suggest that the treatment should be targeted to restoring normal 
methylation patterns to prevent genomic instability caused by DNA hypomethylation. Sporadic 
tumors with CIMP+ phenotype and MSI could benefit from treatment with EZH2 inhibitors and 
demethylating agents, while LS tumors could be treated using demethylating agents in order to 
restore TSG functions or MMR function in cases where MMR gene promoter hypermethylation 
provokes the loss-of-function of the wild-type allele. Molecular profiling can provide opportunities 
for the development of new screening methods allowing earlier diagnosis and thereby improved 
prognosis. Finally, the reversibility of epigenetic states is especially interesting from the 
perspective of drug development. 
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CONCLUSIONS & FUTURE PROSPECTS 
 
Cancer is a very heterogeneous disease. Even though the genetic basis of Lynch syndrome is well 
established, the knowledge of the roles of different epigenetic phenomena in this syndrome is still 
lacking. Also little is known about the background of cancer initiation and the progression of 
microsatellite stable familial tumors (FCCX and FSSEC). These tumor types, as well as sporadic 
cancers, would benefit from a deeper molecular characterization of the tumors and the underlying 
processes in order to provide more adequate diagnostic tools and treatment. 
In this research we focused on certain types of DNA methylation changes and the 
methyltransferases directly affecting DNA methylation in sporadic and familial cancers. Next it 
could be informative to investigate more closely all the genes on DNA methylation pathways in 
our sample collection for possible mutations in normal and tumor tissues and more intensively 
study the global methylation profiles in these tumors using different genome-wide methods. It 
would also be beneficial to investigate the degree of promoter methylation necessary for 
carcinogenesis more closely. Furthermore, the allelic origin of methylation should be determined 
using single-cell analysis methods to see if the methylation events affect both of the alleles or just 
a single allele of a given gene. 
Methyl CpG binding domain proteins (MBDs) e.g. MECP2, MBD1, MBD2, MBD3 and MBD4 are 
capable of specifically binding methylated DNA. Inactivated MBDs can contribute to tumorigenesis 
by disturbing the transcriptional repression and allowing the expression of oncogenes (Du et al., 
2015). For example MBD4 interacts with the DNA mismatch protein MLH1 with DNA repairing 
abilities (Grigera et al., 2013) and is associated with microsatellite instability and MMR defects in 
sporadic cancer. MBD4 deficiency can also cause global hypomethylation by increased C to T 
mutations (Chen et al., 2011). The possible MBD alterations and DNA methylation and 
transcription interactions would be interesting to study especially in MLH1 deficient Lynch 
syndrome patients and FSSEC cases of which 48% in our samples are MMR deficient without 
identified alterations in MMR genes (MLH1, MSH2 or MSH6).  
The entity of FCCX still remains a mystery. The patients fulfil the criteria for HNPCC, but without 
identifiable MMR defects or microsatellite instability. The main aberrations found in this patient 
group are the CIMP+ phenotype without MLH1 methylation in 50% of the cases and a lower global 
methylation status. Germline mutations in BMPR1A (Nieminen et al., 2011) and RPS20 (Nieminen 
et al., 2014) were recently found in few families in the studies of our research group by genome-
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wide linkage scan and next-generation sequencing analyses; methylation studies of BMPR1A and 
RPS20 promoter and enhancer areas as well as related genes might shed light on the mechanisms 
of tumorigenesis in these patients. 
Transcriptional gene regulation is a complex process and besides promoter CpG islands other 
sequences can affect transcription as well. The regulatory regions of a specific gene can be located 
thousands of kilobases up- or downstream of the designated promoter CpG island. 
Characterization of distal enhancers and silencers is another challenge in the investigation of the 
mechanisms and effects of different epigenetic events on mRNA or protein expression. Recent 
studies have also shown that histone modification-directed chromatin organization is closely 
related to mutation rates in CRC (Dominiguez-Valentin et al., 2015). 
Overall, the emerging knowledge of different epigenetic marks by writers, presenters, readers and 
erasers provides an interesting field of study. A better knowledge of the epigenetic phenomena 
and interactions between different epigenetic pathways is necessary to understanding cancer 
development and progression. Epigenetic research has become a hot topic among scientists 
during the past ten years and the rate of new discoveries is increasing. Recent discoveries include 
e.g. the elucidation of the functional roles of DNA demethylation intermediates (Ito et al., 2011), 
5-hydroxymethylcytosine (5hmC) (Severin et al., 2013) and 5-formylcytosine (5fC) (Bachman et 
al., 2015), in gene transcription control. 5hmC levels have been found to associate with stem cell 
pluripotency (Song and He, 2013) and can thus also be important in cancer in context of 
differentiation. The study of the mechanisms and functions of these bases is on the way to be 
extended to cancer research. The functions of different noncoding RNAs are still largely 
undescribed and we remain unaware of the functions of e.g. different histone modifications. 
These for example, are areas in which there is supposedly lot to be discovered in the field of 
cancer. These are at present under continuous study with new effective research methods 
emerging in the field. CpG dinucleotides are the most abundantly methylated and studied in 
mammalian genomes. Epigenetic cancer research is also expanding to investigations of regulatory 
capacities of other methylated dinucleotides (Oster et al., 2013; Kinde et al., 2015; Yamazaki et 
al., 2015). The research could be extended to study the possible functions of other DNA 
modifications that are still uncovered. 
Epigenetic cancer research is now becoming easier by the development of new efficient methods 
by which epigenetic DNA modifications can be easily detected and separated. Also the functional 
properties and interactions of for example alterations of different histone marks can now be 
studied in living cells. While conventional direct genomic sequencing is still useful in detecting 
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mutations or DNA methylation after bisulfite conversion of candidate sequences, 2nd generation 
(or next-generation) amplification-based massively parallel high-throughput sequencing 
technologies are useful in whole genome, exome or methylome studies using bisulfite applications 
and contribute to genome-wide sequencing based personalized medicine. 3rd generation 
sequencing methods based on the sequencing of single-molecules (Bheda and Schneider, 2014), 
of which nanopore sequencing seems at the moment to be the most promising, can in addition to 
normal base detection, distinguish between methylated and hydroxymethylated cytosines and 
other modified or damaged bases and hence gives accurate results directly without error-prone 
amplification steps (Wang et al., 2015). In our study of TSG methylation we concentrated only on 
promoter areas of the selected genes. Whole-genome methylation analyses would give more 
information about the overall methylation changes in different genes and in important control 
regions such as enhancers as well as overlapping, intergenic or intragenic lncRNAs and miRNAs (Li 
et al., 2015). To study the clonal evolution of the tumors, single-cell analyses (Bheda and 
Schneider, 2014) could have been used but because it requires fresh tissue samples it was not 
possible in our samples.  
Cancer processes can be studied and therapies tested using the CRISPR/Cas9 system which is an 
RNA guided site-specific genome-editing tool for studying massive functional interactions in living 
cells (Lu et al., 2015). CRISPR/Cas9 enables the quick modeling of different combinations of 
epigenetic and genetic cancer-related aberrations simultaneously or sequentially (Sander and 
Joung, 2014; Zentner and Henikoff, 2015). By this method the epigenome can be manipulated at 
individual loci and for example fusions of Cas9 to histone-modifying enzymes could allow the 
functional characterization of epigenome. The development of such new technologies and 
databases of functional elements in the human genome, such as The Encyclopedia of DNA 
Elements (ENCODE, 2015) can make the life of an epigenetics researcher much easier and 
epigenetics research much more powerful in the future.
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